EP2495319B1 - Integrin-alpha8beta1-spezifischer monoklonaler antikörper - Google Patents

Integrin-alpha8beta1-spezifischer monoklonaler antikörper Download PDF

Info

Publication number
EP2495319B1
EP2495319B1 EP10824931.9A EP10824931A EP2495319B1 EP 2495319 B1 EP2495319 B1 EP 2495319B1 EP 10824931 A EP10824931 A EP 10824931A EP 2495319 B1 EP2495319 B1 EP 2495319B1
Authority
EP
European Patent Office
Prior art keywords
integrin
antibody
binding
amino acid
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP10824931.9A
Other languages
English (en)
French (fr)
Other versions
EP2495319A1 (de
EP2495319A4 (de
Inventor
Haruo Matuda
Norihisa Nishimichi
Yoshiko Tateishi
Yasuyuki Yokosaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hiroshima University NUC
Original Assignee
Hiroshima University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hiroshima University NUC filed Critical Hiroshima University NUC
Priority to EP18209961.4A priority Critical patent/EP3483267A3/de
Publication of EP2495319A1 publication Critical patent/EP2495319A1/de
Publication of EP2495319A4 publication Critical patent/EP2495319A4/de
Application granted granted Critical
Publication of EP2495319B1 publication Critical patent/EP2495319B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G01N2333/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49

Definitions

  • the present invention relates to anti-integrin ⁇ 8 ⁇ 1 antibodies, and to a process for producing the same.
  • Integrins are expressed on a cell membrane, and constitute a single-transmembrane heterodimeric adhesion molecule. It has been known to have 24 kinds of integrins including 18 types of ⁇ chain and 8 types of ⁇ chain. By binding to its ligand, the recognized integrin transmits various signals to the inside of a cell, and regulates a variety of cellular biological phenomena such as cell morphogenesis, proliferation, and migration of leukocytes at the sites of inflammation.
  • the integrin a8 chain forms a heterodimer with the ⁇ 1 chain to be the integrin ⁇ 8 ⁇ 1.
  • This integrin recognizes RGD stites in extracellular matrix proteins such as fibronectin, vitronectin, tenascin, and osteopontin.
  • the integrin a8 chain is expressed on mesangial cells in a kidney, vascular smooth muscle cells, fibroblasts, or the like. It has been reported in an experiment using knockout mice that the integrin a8 chain is among the most critical integrins during kidney morphogenesis (Non-Patent Document1).
  • Non-Patent Document 2 Detailed physiological functions of this integrin remain unresolved.
  • Non-Patent Document 3 a blocking monoclonal antibody which binds to integrin ⁇ 4 ⁇ 1, having a multiple sclerosis indication (Non-Patent Document 3) has been listed on the market. It has been reported that Vedolizumab exerts a therapeutic effect on inflammatory bowel disease.
  • an anti-integrin ⁇ 8 ⁇ 1 antibody (hereinafter, may be referred to as an "integrin ⁇ 8 ⁇ 1-binding antibody")
  • an antibody which can be used to detect the integrin by Western blotting and an antibody which can be used to detect the integrin by flow cytometry analysis have been described in Non-Patent Document 4.
  • Patent Document 1 discloses an Fc variant of an antibody which binds to integrin ⁇ V ⁇ 3.
  • an embodiment of Patent Document 1 includes integrin ⁇ 8 ⁇ 1 as a candidate for an integrin binding to the Fc variant.
  • Patent Document 2 discloses a recombinant human immunoglobulin having an antigen-binding region containing a particular amino acid sequence. Also, the Claims of Patent Document 2 includes integrin ⁇ 8 ⁇ 1 as an antigen candidate.
  • Non-Patent Documents 1 and 2 describe that expression of integrin ⁇ 8 ⁇ 1 is involved in diseases and tissue morphogenesis, but fail to disclose a functional inhibitor for integrin ⁇ 8 ⁇ 1, a therapeutic agent, or a diagnostic agent so as to improve the above phenomena.
  • a therapeutic agent which exerts a novel mechanism of action or an effect, it has been required to reveal a substance capable of inhibiting an integrin ⁇ 8 ⁇ 1 function or a substance capable of being used for treatment or diagnosis by exerting an effect on integrin ⁇ 8 ⁇ 1.
  • Non-Patent Document 3 describes that an antibody binding to an integrin and inhibiting its functions has exerted a therapeutic effect on a disease. This effect, however, is involved only with integrin ⁇ 4 ⁇ 1, and there is no disclosure regarding integrin ⁇ 8 ⁇ 1. It has been known that integrins have different functions depending on the types of ⁇ chain or ⁇ chain ( Hynes RO., Cell, 2002, Sep. 20, 110(6), 673-87 ). In order to obtain a therapeutic or diagnostic agent which has a novel mechanism of action or an effect, it has been necessary to reveal an antibody binding to integrin ⁇ 8 ⁇ 1 and inhibiting its function.
  • Embodiments of Patent Document 1 include integrin ⁇ 8 ⁇ 1 as a candidate for an integrin binding to an Fc variant of an anti-integrin ⁇ V ⁇ 3 antibody. Patent Document 1, however, discloses nothing about experimental data to prove that. In addition, even if the content of Patent Document 1 is taken into consideration, it is difficult to produce the above Fc variant which binds to integrin ⁇ 8 ⁇ 1.
  • Patent Document 2 set forth integrin ⁇ 8 ⁇ 1 as a candidate for an antigen against a recombinant human immunoglobulin having an antigen-binding region containing a specific amino acid sequence. Patent Document 2, however, discloses nothing about experimental data to prove that. In addition, even if the content of Patent Document 2 is taken into consideration, it is difficult to produce the above recombinant human immunoglobulin which binds to integrin ⁇ 8 ⁇ 1.
  • Non-Patent Document 4 describes antibodies against integrin ⁇ 8 ⁇ 1, but any of those antibodies has been produced as a mouse antibody. Accordingly, those antibodies are presumed not to react with mouse integrin ⁇ 8 ⁇ 1.
  • a therapeutic or diagnostic agent, etc. it is common to examine their effects on organisms such as a human, a mouse, and a rat. Consequently, an antibody having cross-reactivity toward these organisms is needed.
  • many mouse strains have a known genetic background, and also have a property of a short generation time. Further, a mouse is susceptible to diseases similar to those of a human, and is thus an important organism.
  • the present invention has been made in light of the above situation. It is an object of the present invention to provide an anti-integrin ⁇ 8 ⁇ 1 antibody having an effect of inhibiting binding between integrin ⁇ 8 ⁇ 1 and its ligand. In addition, it is another object of the present invention to provide an anti-integrin ⁇ 8 ⁇ 1 antibody which binds to integrin ⁇ 8 ⁇ 1 derived from mammals of different species. Furthermore, it is another object of the present disclosure to provide a process for producing an antibody having a novel property.
  • the present invention is directed to an anti-integrin ⁇ 8 ⁇ 1 antibody as defined in the claims.
  • An aspect of the present invention provides an anti-integrin ⁇ 8 ⁇ 1 antibody as defined in the claims which inhibits binding between integrin ⁇ 8 ⁇ 1 and its ligand.
  • an aspect of the present invention provides an anti-integrin ⁇ 8 ⁇ 1 antibody as defined in the claims which binds to integrin ⁇ 8 ⁇ 1 derived from mammals of different species.
  • an aspect of the present invention provides an anti-integrin ⁇ 8 ⁇ 1 antibody comprising an antibody heavy chain variable region comprising heavy chain CDR1 having an amino acid sequence set forth in SEQ ID No: 1, heavy chain CDR2 having an amino acid sequence set forth in SEQ ID No: 2, and heavy chain CDR3 having an amino acid sequence set forth in SEQ ID No: 3.
  • an anti-integrin ⁇ 8 ⁇ 1 antibody comprising an antibody heavy chain variable region comprising heavy chain CDR1 having an amino acid sequence set forth in SEQ ID No: 4, heavy chain CDR2 having an amino acid sequence set forth in SEQ ID No: 5, and heavy chain CDR3 having an amino acid sequence set forth in SEQ ID No: 6.
  • an anti-integrin ⁇ 8 ⁇ 1 antibody comprising an antibody heavy chain variable region comprising heavy chain CDR1 having an amino acid sequence set forth in SEQ ID No: 7, heavy chain CDR2 having an amino acid sequence set forth in SEQ ID No: 8, and heavy chain CDR3 having an amino acid sequence set forth in SEQ ID No: 9.
  • an aspect of the present invention provides a polynucleotide comprising a nucleotide sequence encoding an anti-integrin ⁇ 8 ⁇ 1 antibody as defined in the claims which inhibits binding between integrin ⁇ 8 ⁇ 1 and its ligand.
  • This polynucleotide comprises a nucleotide sequence encoding an anti-integrin ⁇ 8 ⁇ 1 antibody which has been demonstrated in an Example below to exert an effect of inhibiting the binding between integrin ⁇ 8 ⁇ 1 and its ligand. This results in production of an anti-integrin ⁇ 8 ⁇ 1 antibody from an antibody prepared based on this polynucleotide, the antibody inhibiting the binding between integrin ⁇ 8 ⁇ 1 and its ligand.
  • an aspect of the present invention provides a polynucleotide comprising a nucleotide sequence encoding an anti-integrin ⁇ 8 ⁇ 1 antibody as defined in the claims which binds to integrin ⁇ 8 ⁇ 1 derived from mammals of different species.
  • This polynucleotide comprises a nucleotide sequence encoding an anti-integrin ⁇ 8 ⁇ 1 antibody which has been demonstrated in an Example below to bind to integrin ⁇ 8 ⁇ 1 derived from mammals of different species. This results in production of an anti-integrin ⁇ 8 ⁇ 1 antibody from an antibody prepared based on this polynucleotide, the antibody binding to integrin ⁇ 8 ⁇ 1 derived from mammals of different species.
  • an inhibitor of binding between integrin ⁇ 8 ⁇ 1 and its ligand comprising an anti-integrin ⁇ 8 ⁇ 1 antibody as defined in the claims which inhibits the binding between integrin ⁇ 8 ⁇ 1 and its ligand or an anti-integrin ⁇ 8 ⁇ 1 antibody which binds to integrin ⁇ 8 ⁇ 1 derived from mammals of different species.
  • This inhibitor of binding between integrin ⁇ 8 ⁇ 1 and its ligand contains an anti-integrin ⁇ 8 ⁇ 1 antibody which has been demonstrated in an Example below to exert an effect of inhibiting the binding between integrin ⁇ 8 ⁇ 1 and its ligand. Because of this, use of this inhibitor of binding between integrin ⁇ 8 ⁇ 1 and its ligand enables the binding between integrin ⁇ 8 ⁇ 1 and its ligand to be inhibited depending on various objects such as a therapeutic or diagnostic agent.
  • a therapeutic agent comprising an anti-integrin ⁇ 8 ⁇ 1 antibody as defined in the claims which inhibits binding between integrin ⁇ 8 ⁇ 1 and its ligand or an anti-integrin ⁇ 8 ⁇ 1 antibody which binds to integrin ⁇ 8 ⁇ 1 derived from mammals of different species, wherein the therapeutic agent is used for one or more diseases selected from the group consisting of cancer, arthritis, glaucoma, and neuropathic pain.
  • This therapeutic agent contains an anti-integrin ⁇ 8 ⁇ 1 antibody which has been demonstrated in an Example below to exert an effect of inhibiting the binding between integrin ⁇ 8 ⁇ 1 and its ligand.
  • functions of PI3K or FAK which acts downstream of an integrin ⁇ 8 ⁇ 1-mediated signal transduction mechanism, are inhibited by an antagonist ( Yaguchi et al., J Natl Cancer Inst., 2006, Apr. 19, 98(8), 545-56 ), it is described that a therapeutic effect has been exerted in vivo on an animal model for cancer.
  • this therapeutic agent can achieve a therapeutic effect on cancer, arthritis, glaucoma, or neuropathic pain by inhibiting signaling through integrin ⁇ 8 ⁇ 1 to PI3K or FAK.
  • a diagnostic agent comprising an anti-integrin ⁇ 8 ⁇ 1 antibody as defined in the claims which inhibits binding between integrin ⁇ 8 ⁇ 1 and its ligand or an anti-integrin ⁇ 8 ⁇ 1 antibody which binds to integrin ⁇ 8 ⁇ 1 derived from mammals of different species, wherein the diagnostic agent is used for one or more diseases selected from the group consisting of pulmonary fibrosis, hepatic fibrosis, renal failure, and inner ear disease.
  • This diagnostic agent contains an anti-integrin ⁇ 8 ⁇ 1 antibody which has been demonstrated in an Example below to exert an effect of inhibiting the binding between integrin ⁇ 8 ⁇ 1 and its ligand or an anti-integrin ⁇ 8 ⁇ 1 antibody which has been demonstrated in an Example below to bind to integrin ⁇ 8 ⁇ 1 derived from mammals of different species. It is described that integrin ⁇ 8 ⁇ 1 is highly expressed in pulmonary fibrosis or hepatic fibrosis ( Levine et al., Am J Pathol., 2000, Jun., 156(6), 1927-35 ). Also, in an integrin a8 chain-knockout mouse, it has been described that kidney morphogenesis failure happens ( Muller et al., Cell, 1997, Mar.
  • a diagnostic agent comprising an anti-integrin ⁇ 8 ⁇ 1 antibody as defined in the claims which inhibits binding between integrin ⁇ 8 ⁇ 1 and its ligand or an anti-integrin ⁇ 8 ⁇ 1 antibody which binds to integrin ⁇ 8 ⁇ 1 derived from mammals of different species, wherein the diagnostic agent is used for one or more diseases selected from the group consisting of cancer, arthritis, glaucoma, and neuropathic pain.
  • This diagnostic agent contains an anti-integrin ⁇ 8 ⁇ 1 antibody which has been demonstrated in an Example below to exert an effect of inhibiting the binding between integrin ⁇ 8 ⁇ 1 and its ligand or an anti-integrin ⁇ 8 ⁇ 1 antibody which has been demonstrated in an Example below to bind to integrin ⁇ 8 ⁇ 1 derived from mammals of different species.
  • functions of PI3K or FAK which acts downstream of an integrin ⁇ 8 ⁇ 1-mediated signal transduction mechanism, are inhibited by an antagonist, it is described that a therapeutic effect has been exerted in vivo on an animal model for cancer, arthritis, glaucoma, or neuropathic pain. Accordingly, use of this diagnostic agent along with a diagnosis protocol known in the art allows for diagnosis of cancer, arthritis, glaucoma, or neuropathic pain.
  • an aspect of the present disclosure provides a process for producing an antibody as defined in the claims, the process comprising the step of immunizing a chicken with an antigen containing antigenic protein-expressing cells or an antigen containing a cell membrane having an antigenic protein.
  • This production process has been proved in a below-described Example to be able to produce an antibody having properties different from those of antibodies as obtained using a conventional production process. Consequently, use of this production process can produce an antibody having properties different from those of antibodies as obtained using a conventional production process.
  • Embodiments of the present invention provide anti-integrin ⁇ 8 ⁇ 1 antibodies as defined in the claims which inhibit binding between integrin ⁇ 8 ⁇ 1 and its ligand, anti-integrin ⁇ 8 ⁇ 1 antibodies as defined in the claims which bind to integrin ⁇ 8 ⁇ 1 derived from mammals of different species, or inhibitors of binding between integrin ⁇ 8 ⁇ 1 and its ligand, the inhibitors containing an anti-integrin ⁇ 8 ⁇ 1 antibody as defined in the claims.
  • aspects of the present disclosure allow for a process for producing an antibody as defined in the claims having a novel property.
  • the present inventors have been conducting research which aims to functionally analyze integrin ⁇ 8 ⁇ 1 and to improve performance of an anti-integrin ⁇ 8 ⁇ 1 antibody so as to develop a therapeutic agent, a diagnostic agent, or a research reagent (material).
  • a correlation with various diseases has been reported, including that integrin ⁇ 8 ⁇ 1 is involved in kidney morphogenesis and is highly expressed in a mouse lung affected by pulmonary fibrosis.
  • details on physiological functions remain unresolved in many points.
  • the present inventors have sought for an anti-integrin ⁇ 8 ⁇ 1 antibody.
  • various points have been considered, including an immune animal, panning selection, and the like.
  • the antibody when the resulting antibody has been examined regarding its cross-reactivity, the antibody, remarkably, binds to integrin ⁇ 8 ⁇ 1 derived from both a human and a mouse.
  • the antibody has an activity of inhibiting the binding between integrin ⁇ 8 ⁇ 1 and its ligand. Accordingly, an antibody exerting an effect which cannot be previously predicted has been successfully obtained, and the present invention has been completed.
  • An integrin is a receptor present on the surface of a plasma membrane as a heterodimer consisting of an ⁇ chain and a ⁇ chain.
  • the integrin has been reported to function mainly as a receptor for an extracellular matrix. Its ligand binding triggers binding of its cytoplasmic domain to a molecule such as FAK or talin, and transmits a signal into a nucleus ( FIG. 1 ). Its subunits include 18 ⁇ chains and 8 ⁇ chains. A total of 24 kinds of the integrin are known to exist ( FIG. 2 ). Although each integrin has ligand selectivity, its ligand overlaps ( FIG. 3 ). Deletion of any subunit causes either lethality or phenotypic changes.
  • every subunit is said to be indispensable for survival or health maintenance.
  • normal cells contact some extracellular matrix, and an integrin-mediated signal is said to be constitutively transduced. If the composition of the matrix surrounding a cell is changed, the cell recognizes such a change via integrins. Also, the integrins have a crosstalk with a growth factor signal, and are known to function cooperatively. There are many reports that the integrin signal plays a role in cell differentiation, cell proliferation, cell death, or the like.
  • Integrin a8 chain and ⁇ 1 chain form a heterodimer.
  • This integrin is known to have specificity for a ligand containing an RGD motif, the ligand including fibronectin, vitronectin, tenascin, osteopontin, or the like.
  • the integrin a8 chain is expressed in kidney mesangial cells, vascular smooth muscle cells, fibroblasts, or the like. Experiments using its knockout mouse reportedly demonstrate that in particular, this integrin is critical in kidney morphogenesis ( Muller et al., Cell, 1997, Mar. 7, 88(5), 603-13 ).
  • An embodiment of the present invention provides anti-integrin ⁇ 8 ⁇ 1 antibodies as defined in the claims.
  • the above anti-integrin ⁇ 8 ⁇ 1 antibodies include an anti-integrin ⁇ 8 ⁇ 1 antibody that inhibits binding between integrin ⁇ 8 ⁇ 1 and its ligand. Accordingly, use of the above anti-integrin ⁇ 8 ⁇ 1 antibody seems to be able to inhibit various functions that are responsible for signal transduction involved with integrin ⁇ 8 ⁇ 1, the functions including, for example, PI3K (phosphoinositide 3-kinase) activation ( Hynes RO., Cell, 2002, Sep. 20, 110(6), 673-87 ; Farias et al., Biochem Biophys Res Commun., 2005, Apr.
  • PI3K phosphoinositide 3-kinase
  • the above anti-integrin ⁇ 8 ⁇ 1 antibodies may include an anti-integrin ⁇ 8 ⁇ 1 antibody that binds to integrin ⁇ 8 ⁇ 1 derived from mammals of different species.
  • use of the above anti-integrin ⁇ 8 ⁇ 1 antibody as a detection probe enables the localization of integrin ⁇ 8 ⁇ 1 to be investigated in mammalian tissues and cells etc.
  • the above anti-integrin ⁇ 8 ⁇ 1 antibody can be suitably used as a component for an agent (e.g., a therapeutic agent) that is important to examine its effect on multiple organisms.
  • the integrin ⁇ 8 ⁇ 1 binding to the above anti-integrin ⁇ 8 ⁇ 1 antibody may be integrin ⁇ 8 ⁇ 1 derived from a human and any of one or more organisms preferably selected from a mouse, a rat, a guinea pig, a rabbit, a pig, a sheep, cattle, a horse, a cat, a dog, a monkey, and a chimpanzee.
  • a therapeutic or diagnostic agent for a human disease a mouse, a rat, a rabbit, a pig, a sheep, cattle, a horse, a cat, a dog, a monkey, or a chimpanzee may serve as a mammal which can be used as a typical disease model animal.
  • the foregoing mammal may include a human and any of one or more organisms more preferably selected from a mouse, a rat, a guinea pig, a monkey, and a chimpanzee.
  • mice are commonly used in the world as a research model animal and many of their properties have been revealed.
  • many mouse strains have a known genetic background, also have a property of a short generation time, and further are susceptible to diseases similar to those of a human. Hence, a mouse is preferable.
  • binding means a link between substances.
  • the link may be either a covalent bond or a noncovalent bond, and includes, for example, an ionic bond, a hydrogen bond, a hydrophobic interaction, or a hydrophilic interaction.
  • the above anti-integrin ⁇ 8 ⁇ 1 antibodies may include a recombinant protein produced from cells derived from a human or another mammal (e.g., a rat, a mouse, a rabbit, cattle, a monkey, a pig, a horse, a sheep, a goat, a dog, a cat, a guinea pig, a hamster) having any of a polynucleotide encoding the above anti-integrin ⁇ 8 ⁇ 1 antibody, a vector containing a polynucleotide encoding the above anti-integrin ⁇ 8 ⁇ 1 antibody, and a vector containing a portion of a polynucleotide encoding the above anti-integrin ⁇ 8 ⁇ 1 antibody.
  • a recombinant protein produced from cells derived from a human or another mammal (e.g., a rat, a mouse, a rabbit, cattle, a monkey, a pig, a horse, a
  • mammalian cells can include monkey COS-7 cells, Vero cells, Chinese hamster CHO cells (CHO cells), dhfr-deficient Chinese hamster CHO cells (CHO (dhfr) cells), mouse L cells, mouse AtT-20 cells, mouse myeloma cells, rat GH3 cells, human FL cells, human HEK293 cells, and the like.
  • the above anti-integrin ⁇ 8 ⁇ 1 antibodies may include a recombinant protein produced from Escherichia bacteria, Bacillus bacteria, yeasts, or insect cells.
  • examples of the above vector which can be used include Escherichia coli-derived plasmids (e.g., pBR322, pBR325, pUC12, pUC13), Bacillus subtilis-derived plasmids (e.g., pUB110, pTP5, pC194), yeast-derived plasmids (e.g., pSH19, pSH15), bacteriophages (e.g., a ⁇ phage), animal viruses (e.g., a retrovirus, a vaccinia virus, a baculovirus), pA1-11, pXT1, pRc/CMV, pRc/RSV, pcDNAI/Neo, and the like.
  • Escherichia coli-derived plasmids e.g., pBR322, pBR325, pUC12, pUC13
  • Bacillus subtilis-derived plasmids e.
  • the above polynucleotide or vector can be introduced into cells and the antibody can be produced in accordance with a method known in the art.
  • a method which can be used for expressing an antibody in a cell include a calcium phosphate method, lipofection, electroporation, an adenovirus-mediated method, a retrovirus-mediated method, microinjection, and the like (" Genetic Engineering Handbook", 4th Edition, YODOSHA CO., LTD. (2003): 152-179 ).
  • the above anti-integrin ⁇ 8 ⁇ 1 antibodies may be a protein which is chemically synthesized or synthesized using a cell-free translation system.
  • anti-integrin ⁇ 8 ⁇ 1 antibodies can be purified from anti-integrin ⁇ 8 ⁇ 1 antibody-producing cells by using a method known in the art.
  • a method for purifying an antibody include ammonium sulfate precipitation or ethanol precipitation, Protein A, Protein G, or gel filtration chromatography, anion or cation-exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography, lectin chromatography, and the like (" Protein Experiment Handbook", YODOSHA CO., LTD., 2003, 27-52 ).
  • the above anti-integrin ⁇ 8 ⁇ 1 antibodies include an antibody which binds to wild type or mutant integrin ⁇ 8 ⁇ 1.
  • the term "mutant" includes being responsible for a DNA sequence variation among individuals.
  • the above anti-integrin ⁇ 8 ⁇ 1 antibodies are preferably a wild type. In the case of a mutant, the mutant has preferably 80% or more homology to the wild type, more preferably 90% or more homology, and still more preferably 95% or more homology. This is because if the mutant has an amino acid sequence having higher homology to the wild type, functions similar to those of an anti-integrin ⁇ 8 ⁇ 1 antibody which has been verified to inhibit the binding between integrin ⁇ 8 ⁇ 1 and its ligand are obtained.
  • the term "homology” refers to a ratio of the number of identical amino acids between two or among a plurality of amino acid sequences to the total number of amino acids as calculated by using a process known in the art. Before the calculation of the ratio, amino acid sequences selected from the group of amino acid sequences compared are aligned. If the ratio of the identical amino acids is required to be optimized, gaps are inserted in some portions of the amino acid sequence. In addition, any conservative substitution is not considered to be identical. Also, the term means a ratio of the number of identical amino acids to the total number of amino acid residues including overlapping amino acids while keeping the optimal alignment.
  • An alignment method, a ratio calculation process, and a related computer program are conventionally well known in the art. A common sequence analysis program (e.g., GENETYX, Gene Chip Sequence Analysis) can be used for measurements.
  • the above anti-integrin ⁇ 8 ⁇ 1 antibodies may include an anti-integrin ⁇ 8 ⁇ 1 antibody whose heavy chain variable region comprises heavy chain CDR1 having an amino acid sequence set forth in SEQ ID No: 1, heavy chain CDR2 having an amino acid sequence set forth in SEQ ID No: 2, and heavy chain CDR3 having an amino acid sequence set forth in SEQ ID No: 3.
  • the antibody light chain variable region of the foregoing anti-integrin ⁇ 8 ⁇ 1 antibody may comprise light chain CDR1 having an amino acid sequence set forth in SEQ ID No: 10, light chain CDR2 having an amino acid sequence set forth in SEQ ID No: 11, and light chain CDR3 having an amino acid sequence set forth in SEQ ID No: 12.
  • an anti-integrin ⁇ 8 ⁇ 1 antibody whose heavy chain variable region comprises heavy chain CDR1 having an amino acid sequence set forth in SEQ ID No: 4, heavy chain CDR2 having an amino acid sequence set forth in SEQ ID No: 5, and heavy chain CDR3 having an amino acid sequence set forth in SEQ ID No: 6.
  • the antibody light chain variable region of the foregoing anti-integrin ⁇ 8 ⁇ 1 antibody may comprise light chain CDR1 having an amino acid sequence set forth in SEQ ID No: 13, light chain CDR2 having an amino acid sequence set forth in SEQ ID No: 14, and light chain CDR3 having an amino acid sequence set forth in SEQ ID No: 15.
  • an anti-integrin ⁇ 8 ⁇ 1 antibody whose heavy chain variable region comprises heavy chain CDR1 having an amino acid sequence set forth in SEQ ID No: 7, heavy chain CDR2 having an amino acid sequence set forth in SEQ ID No: 8, and heavy chain CDR3 having an amino acid sequence set forth in SEQ ID No: 9.
  • the antibody light chain variable region of the foregoing anti-integrin ⁇ 8 ⁇ 1 antibody may comprise light chain CDR1 having an amino acid sequence set forth in SEQ ID No: 16, light chain CDR2 having an amino acid sequence set forth in SEQ ID No: 17, and light chain CDR3 having an amino acid sequence set forth in SEQ ID No: 18.
  • anti-integrin ⁇ 8 ⁇ 1 antibodies containing the above specific CDRs are demonstrated in the below-described Examples to inhibit the binding between integrin ⁇ 8 ⁇ 1 and its ligand or to bind to any of human- and mouse- derived integrin ⁇ 8 ⁇ 1.
  • amino acid sequences set forth in the above SEQ ID Nos: 1, 4, 7, 11, 14, and 17 may have one amino acid deletion, substitution, or addition of the respective amino acid sequences. Even in the case of there being such a deletion, etc., of the amino acid sequences included in the above anti-integrin ⁇ 8 ⁇ 1 antibodies, a similar effect seems to be exerted, compared to that of the case of there being no deletion etc. Also, the above term “addition” includes a concept of insertion.
  • amino acid sequences set forth in the above SEQ ID Nos: 2, 3, 5, 6, 8, and 9 may have one to three amino acid deletions, substitutions, or additions of the respective amino acid sequences. Even in the case of there being such a deletion, etc., of the amino acid sequences included in the above anti-integrin ⁇ 8 ⁇ 1 antibodies, a similar effect seems to be exerted, compared to that of the case of there being no deletion etc.
  • the above term “one to three” refers to preferably “one to two", and more preferably "one”. This is because when the above "one to three” refers to a less number, it indicates that the antibody has properties more similar to those of the anti-integrin ⁇ 8 ⁇ 1 antibody without deletion, etc., of its amino acid sequence.
  • amino acid sequences set forth in the above SEQ ID Nos: 10, 12, 13, 15, 16, and 18 may have one to two amino acid deletions, substitutions, or additions of the respective amino acid sequences. Even in the case of there being such a deletion, etc., of the amino acid sequences included in the above anti-integrin ⁇ 8 ⁇ 1 antibodies, a similar effect seems to be exerted, compared to that of the case of there being no deletion etc.
  • the above term “one to two” refers to preferably "one”. This is because when the above "one to two” refers to a less number, it indicates that the antibody has properties more similar to those of the anti-integrin ⁇ 8 ⁇ 1 antibody without deletion of its amino acid sequence.
  • any amino acid can be used for amino acids denoted by Xaa.
  • the heavy chain CDR1 contains xxDMx
  • the heavy chain CDR2 contains IxxxxSxxxYxxAVKG
  • the heavy chain CDR3 contains xxxxYxxxGxxxxxxxID
  • the light chain CDR1 contains SGxxxSxYG
  • the light chain CDR2 contains xxxxRPS
  • the light chain CDR3 contains Gxxxxxxxxxxx.
  • the symbol "x" represents an amino acid which is different from or deleted from the standard amino acid sequence set forth in that of the antibody No. 3.
  • the above anti-integrin ⁇ 8 ⁇ 1 antibodies may be encoded by plasmids including Accession No: NITE BP-824, Accession No: NITE BP-825, Accession No: NITE BP-826, Accession No: NITE BP-827, Accession No: NITE BP-828, or Accession No: NITE BP-829.
  • the above anti-integrin ⁇ 8 ⁇ 1 antibodies may comprise an amino acid sequence of or an amino acid sequence having 80% or more homology to a heavy chain V H , heavy chain CDR 1 to 3, light chain V L , or light chain CDR 1 to 3 of antibodies encoded by the above plasmids.
  • 80% or more refers to preferably having 85% or more, more preferably having "90% or more", and still more preferably having 95% or more. This is because the higher the homology is, the more their properties are similar to those of the antibodies encoded by the above plasmids.
  • DNA sequence and the amino acid sequence of integrin ⁇ 8 ⁇ 1 are publicly known.
  • GenBank a database of National Center for Biotechnology Information (NCBI), etc., can be used for reference.
  • the term "antibody” refers to a molecule which specifically binds to a specific epitope localized on an antigen, and the term includes a polyclonal antibody and a monoclonal antibody.
  • the antibody can exist as various forms. Examples of the forms can include Fv, Fab, F(ab')2, Fab', a diabody, a single-chain antibody (e.g., scFv, dsFv), a CDR-containing peptide, a multivalent antibody (e.g., a divalent antibody), a mouse chimeric antibody, a chicken chimeric antibody, a humanized antibody, a human antibody, and the like.
  • the forms having a low-molecular-weight antibody or sugar-chain-modified antibody combined with a chemically synthesized existing pharmaceutical agent or pharmaceutical product may be allowed.
  • the antibody In order to decrease immunogenicity when the antibody is used as a therapeutic agent, it is preferable for the antibody to have a high proportion of a human-derived amino acid sequence.
  • the antibody is preferably a chimeric antibody with human-derived regions, more preferably a humanized antibody, and most preferably a human antibody.
  • the antibody in order to decrease immunogenicity or increase stability when the antibody is used as a therapeutic agent, it is preferable for the antibody to be a lower-molecular-weight molecule as long as the antibody possesses desired functions.
  • a polyclonal antibody described herein can be generated by administering an immunogen containing a target antigen to a mammal (e.g., a rat, a mouse, a rabbit, a chicken, cattle, a monkey, a pig, a horse, a sheep, a goat, a dog, a cat, a guinea pig, a hamster) or a bird (e.g., a chicken) so as to induce production of a serum containing an antigen-specific polyclonal antibody.
  • Administration of the immunogen may require coinjection of one or more immunizing agents and an adjuvant as desired.
  • the adjuvant may be used for enhancing an immune response.
  • the adjuvant examples include (complete or incomplete) Freund adjuvant, a mineral gel (e.g., aluminum hydroxide), a surfactant (e.g., lysolecithin, pluronic polyol, a polyanion, a peptide, oil emulsion, keyhole limpet hemocyanin, dinitrophenol), and a potentially useful human adjuvant (e.g., Bacille Calmette-Guerin (BCG) or Corynebacterium parvum).
  • BCG Bacille Calmette-Guerin
  • the examples further include MPL-TDM adjuvant (monophosphoryl lipid A, synthetic trehalosedicorynomycolate) as well.
  • An immunization protocol is publicly known in the art. Any method for inducing an immune response in a selected host animal may be carried out (" Protein Experiment Handbook", YODOSHA CO., LTD. (2003), 86-91 ).
  • the term "monoclonal antibody” refers to an antibody collected from a substantially pure antibody population. That is, individual antibodies constituting a population include identical ones except the antibodies having mutations that can be present in a small number of cases and that can naturally occur.
  • a monoclonal antibody is highly specific, and corresponds to one antigenic site. Further, the monoclonal antibody is distinct from a typical polyclonal antibody commonly containing different antibodies corresponding to different epitopes (antigen determinants). Each monoclonal antibody corresponds to a single epitope of an antigen. In addition to its specificity, the monoclonal antibody is useful in view of synthesizing the antibody by hybridoma culture without having contamination of other immunoglobulins.
  • the modifier "monoclonal” indicates a feature of an antibody which has been obtained from a substantially pure antibody population, but does not mean that the antibody has to be produced by any particular method.
  • the monoclonal antibody described herein can be produced by a method similar to a hybridoma method disclosed in Kohler G and Milstein C., Nature, 1975, Aug. 7, 256 (5517), 495-497 .
  • the monoclonal antibody used in embodiments of the present invention can be produced by a method similar to the recombinant technology disclosed in U.S. Patent No. 4816567 .
  • the monoclonal antibody used herein can be isolated from a phage antibody library by a method similar to the technology described in Clackson et al., Nature, 1991, Aug. 15, 352 (6336), 624-628 or Marks et al., J Mol Biol., 1991, Dec. 5, 222(3), 581-597 .
  • the antibody can be generated by a general production procedure disclosed in " Protein Experiment Handbook", YODOSHA CO., LTD., (2003), 92-96 .
  • the monoclonal antibody used herein is preferably generated by a procedure described in Examples below.
  • Fv is an antibody fragment containing a complete antigen-recognition and antigen-binding site.
  • This Fv region consists of a dimer between variable domains of one heavy chain and one light chain which form tight non-covalent bonds.
  • three CDRs of the respective variable domains interact with one another to form an antigen binding site on the surface of the V H -V L dimer. Accordingly, these six CDRs give an antibody an antigen-binding specificity.
  • any known process can be employed as its production process.
  • the Fv can be produced by inserting a DNA encoding Fv of an anti-integrin ⁇ 8 ⁇ 1 antibody described herein into a prokaryotic expression vector or a eukaryotic expression vector, and by introducing the vector into a prokaryote or a eukaryote to express the DNA.
  • Fab is an antibody fragment having an antigen-binding activity, the fragment being obtained by treating IgG with a protease, papain, and the fragment having the N-terminal half of the H chain and the entire L chain linked via a disulfide bond. Then, any known process can be employed as its production process.
  • the Fab can be produced by treating an anti-integrin ⁇ 8 ⁇ 1 antibody with a protease, papain.
  • the Fab can be produced by inserting a DNA encoding Fab of an anti-integrin ⁇ 8 ⁇ 1 antibody into a prokaryotic expression vector or a eukaryotic expression vector, and by introducing the vector into a prokaryote or a eukaryote to express the DNA.
  • F(ab') 2 is an antibody fragment having an antigen-binding activity, the fragment being obtained by treating IgG with a protease, pepsin, and the fragment having a little larger portion than Fabs whose hinge regions are linked via disulfide bonds. Then, any known process can be employed as its production process.
  • the F(ab') 2 can be produced by treating an anti-integrin ⁇ 8 ⁇ 1 antibody with a protease, pepsin.
  • the F(ab') 2 can be produced by linking the following Fab's via a thioether bond or a disulfide bond.
  • Fab' is an antibody fragment having an antigen-binding activity, the fragment being produced by cleaving the disulfide bonds in the hinge regions of the F(ab') 2 .
  • the Fab' can be produced by treating the F(ab') 2 with a reducing agent, dithiothreitol. Then, any known process can be employed as its production process.
  • the Fab' can be produced by inserting a DNA encoding Fab' fragment of an anti-integrin ⁇ 8 ⁇ 1 antibody described herein into a prokaryotic expression vector or a eukaryotic expression vector, and by introducing the vector into a prokaryote or a eukaryote to express the DNA.
  • scFv is an antibody fragment having an antigen-binding activity, the fragment being a polypeptide having one V H and one V L linked by a suitable peptide linker.
  • any known process can be employed as the production process.
  • the scFv can be produced by obtaining cDNAs encoding V H and V L of an anti-integrin ⁇ 8 ⁇ 1 antibody described herein, by constructing a DNA encoding the scFv, by inserting the DNA into a prokaryotic expression vector or a eukaryotic expression vector, and by introducing the vector into a prokaryote or a eukaryote to express the DNA.
  • a diabody is an antibody fragment having divalent antigen-binding activities, the fragment having scFvs dimerized. Both of the divalent antigen-binding activities can be identical, or one of them can be a distinct antigen-binding activity. Then, any known process can be employed as its production process.
  • the diabody can be produced by obtaining cDNAs encoding V H and V L of an anti-integrin ⁇ 8 ⁇ 1 antibody described herein, by constructing a DNA encoding scFv using a peptide linker whose length in its amino acid sequence is 8 residues or shorter, by inserting the DNA into a prokaryotic expression vector or a eukaryotic expression vector, and by introducing the vector into a prokaryote or a eukaryote to express the DNA.
  • dsFv is a general term referring to a polypeptide having one amino acid residue in the respective V H and the V L substituted by a cysteine residue, followed by linking the cysteine residues via a disulfide bond.
  • the amino acid residue substituted by the cysteine residue can be selected based on an antibody conformation prediction in accordance with a procedure indicated by Reiter et al. ( Reiter et al., Protein Eng., 1994, May, 7(5), 697-704 ). Then, any known process can be employed as its production process.
  • the dsFv can be produced by obtaining cDNAs encoding V H and V L of an anti-integrin ⁇ 8 ⁇ 1 antibody described herein, by constructing a DNA encoding the dsFv, by inserting the DNA into a prokaryotic expression vector or a eukaryotic expression vector, and by introducing the vector into a prokaryote or a eukaryote to express the DNA.
  • a peptide containing a CDR includes at least one CDR of either V H or V L .
  • a plurality of peptides containing a CDR can be linked directly or indirectly via a suitable peptide linker. Then, any known process can be employed as its production process.
  • the peptide containing a CDR can be produced by constructing a DNA encoding a CDR of V H or V L of an anti-integrin ⁇ 8 ⁇ 1 antibody described herein, by inserting the DNA into a prokaryotic expression vector or a eukaryotic expression vector, and by introducing the vector into a prokaryote or a eukaryote to express the DNA.
  • the peptide containing a CDR can also be produced by a chemical synthesis process such as an Fmoc (fluorenylmethyloxycarbonyl) process and a tBOC (t-butyloxycarbonyl) process.
  • a chemical synthesis process such as an Fmoc (fluorenylmethyloxycarbonyl) process and a tBOC (t-butyloxycarbonyl) process.
  • a chimeric antibody can be produced by linking variable regions of an antibody derived from a non-human species to a constant region of a human antibody, and can be easily constructed using gene recombinant technology.
  • a process for producing a chimeric antibody is known in the art.
  • a mouse-human chimeric antibody can be produced by a process disclosed in Roguska et al., Proc Natl Acad Sci U S A., 1994, Feb. 1, 91(3), 969-973 .
  • the mouse-human chimeric antibody can be obtained by cloning DNA fragments encoding V regions of mouse light and heavy chains of a murine monoclonal antibody against a target antigen, by linking DNAs encoding these murine V regions to DNAs encoding constant regions of a human antibody, and by expressing the DNAs.
  • a basic procedure for producing a mouse-human chimeric antibody includes: isolating a mouse leader sequence and a V region sequence present in a cloned cDNA; and linking these sequences to a sequence encoding a C region of a human antibody, the sequence being present in a mammalian expression vector.
  • a murine leader sequence and a V region sequence present in a cloned cDNA are first linked to a sequence encoding a C region of a human antibody and the resulting sequence is then ligated into a mammalian expression vector.
  • a fragment of the C region of the human antibody can be a C region of an H chain or a C region of an L chain of any human antibody. Examples of the C region of the human H chain can include C ⁇ 1, C ⁇ 2, C ⁇ 3 and C ⁇ 4. Examples of the C region of the L chain can include C ⁇ and C ⁇ .
  • a humanized antibody has one or more complementarity determining regions (CDRs) derived from a non-human species, human-immunoglobulin-derived framework regions (FRs), and human-immunoglobulin-derived constant regions.
  • CDRs complementarity determining regions
  • FRs human-immunoglobulin-derived framework regions
  • human-immunoglobulin-derived constant regions The humanized antibody binds to a desired antigen.
  • amino acid residues in the human framework regions are frequently substituted by residues corresponding to those of the CDR-donor antibody.
  • framework substitutions are carried out using a procedure well-known in the art (e.g., by modeling of an interaction between CDR and framework residues so as to identify a critical framework residue for the antigen binding, and by sequence comparison so as to identify an abnormal framework residue in a particular position)( Riechmann et al., Nature, 1988, Mar. 24, 332(6162), 323-327 ).
  • An antibody can be humanized by using various techniques known in the art ( Almagro et al., Front Biosci., 2008, Jan. 1, 13, 1619-1633 ). Examples of the techniques can include CDR grafting ( Ozaki et al., Blood, 1999, Jun.
  • a human antibody has a heavy chain variable region, a heavy chain constant region, a light chain variable region, and a light chain constant region, all of which are derived from genes encoding a human immunoglobulin.
  • the human antibody has less immunogenicity at the time of administration to a human, and can thus preferably be used for treatment of human diseases.
  • Examples of a basic method for generating a human antibody include a method using a human-antibody-producing transgenic mouse, phage display, and the like.
  • the method using a human-antibody-producing transgenic mouse includes: introducing a functional human Ig gene into an endogenous-Ig-knockout mouse; and producing, instead of a mouse antibody, a human antibody having versatile antigen-binding abilities.
  • a human monoclonal antibody can be obtained using a conventional hybridoma procedure.
  • the human antibody can be prepared using a method disclosed in Lonberg et al., Int Rev Immunol., 1995, 13(1), 65-93 .
  • the phage display is a system in which an exogenous gene is made to be expressed as a fusion protein at an N-terminal portion of a coat protein (e.g., g3p, g10p) of a filamentous phage such as M13 and T7, an E. coli virus, without losing infectivity of the phage.
  • the human antibody can be prepared using a method disclosed in Vaughan et al., Nat Biotechnol., 1996, Mar., 14(3), 309-314 .
  • amino acids of the above anti-integrin ⁇ 8 ⁇ 1 antibodies are substituted by other amino acids
  • the amino acids are preferably substituted by other amino acids which are conserved in their side chain characteristics.
  • the characteristics of the amino acid side chain can include hydrophobic amino acids (e.g., A, I, L, M, F, P, W, Y, V), hydrophilic amino acids (e.g., R, D, N, C, E, Q, G, H, K, S, T), amino acids having an aliphatic side chain (e.g., G, A, V, L, I, P), amino acids having a hydroxy-containing side chain (e.g., S, T, Y), amino acids having a sulfur-containing side chain (e.g., C, M), amino acids having a carboxylic-acid-containing or amido-containing side chain (e.g., D, N, E, Q), amino acids having a base-containing side chain (e.g., R, K, H), and amino acids
  • a substitution of an amino acid by an amino acid within each group is generally referred to as a conservative substitution. It has been already known that a polypeptide having its amino acid sequence modified by one or several amino acid residue deletions, additions, or substitutions can maintain its biological activity ( Mark et al., Proc Natl Acad Sci U S A., 1984, Sep., 81(18), 5662-5666 ; Zoller et al., Nucleic Acids Res., 1982, Oct. 25, 10(20), 6487-6500 ; and Wang et al., Science, 1984, Jun. 29, 224(4656), 1431-1433 ).
  • the above anti-integrin ⁇ 8 ⁇ 1 antibodies may be affinity-matured by using an existing selection or mutagenesis.
  • An affinity-matured antibody has preferably 5 times higher affinity than a starting antibody, more preferably 10 times higher affinity, and still more preferably 20 or 30 times higher affinity.
  • biopanning utilizing an antibody phage library can be used.
  • a typical manipulation of this method includes steps of: reacting an immobilized target protein with an antibody phage library; removing an unbound phage antibody by washing; eluting a bound phage antibody; and infecting Escherichia coli with the bound phage antibody. Repeating the above steps several times can produce a phage antibody specific to the target protein (" Antibody Experiment Manual", Revised Version, YODOSHA CO., LTD. (2008), 211-221 ).
  • Examples of a class of the above anti-integrin ⁇ 8 ⁇ 1 antibodies include IgM, IgD, IgG, IgA, IgE, IgX, IgY, IgW, and IgNAR.
  • the class is IgM, IgD, IgG, IgA, or IgE. This is because IgM, IgD, IgG, IgA, and IgE are classes of a human-derived antibody.
  • the antibody when used as a therapeutic agent, its immunogenicity is highly likely to decrease.
  • the heavy chain CDR1, heavy chain CDR2, or heavy chain CDR3 of the above anti-integrin ⁇ 8 ⁇ 1 antibodies may be derived from, for example, a human, another mammal (e.g., a rat, a mouse, a rabbit, cattle, a monkey, a pig, a horse, a sheep, a goat, a dog, a cat, a guinea pig, a hamster), or a bird (e.g., a chicken).
  • those derived from a human or mouse are preferable. This is because those derived from a human can decrease immunogenicity at the time of administration to a human.
  • a mouse is most frequently used for antibody production, so that information has been already accumulated. Besides, how to use the antibody is easier.
  • the above anti-integrin ⁇ 8 ⁇ 1 antibodies can be obtained by isolating a DNA encoding CDRs of the heavy chain of the above anti-integrin ⁇ 8 ⁇ 1 antibodies and a DNA encoding regions, other than the CDRs of the heavy chain, of a known antibody derived from a human or non-human organism, by ligating these DNAs into a vector in accordance with a procedure known in the art, and then by expressing these DNAs.
  • FR regions are preferably optimized by using FR shuffling ( Damschroder et al., Mol Immunol., 2007, Apr., 44(11), 3049-3060 , Epub 2007 Jan 22) or a process for substituting amino acid residues within a vernier zone and/or packaging residues ( JP2006-241026A or Foote et al., J Mol Biol., 1992, Mar. 20, 224(2), 487-499 ).
  • Another aspect of the present disclosure provides a process for producing an antibody as defined in the claims.
  • the above process for producing an antibody includes the step of immunizing a chicken with an antigen containing cells expressing an antigenic protein or an antigen containing a cell membrane having the antigenic protein. According to this production process, it is possible to produce an antibody recognizing an antigenic site different from a site in the case of using an antigen such as a short peptide fragment of the antigenic protein.
  • the produced antibody that binds to the antigenic protein can be used as a therapeutic or diagnostic agent, etc., for various diseases involving the antigenic protein.
  • the above production process may further include the steps of: reacting a chicken-derived antibody library with the cells expressing the antigenic protein or the cell membrane having the antigenic protein; and selecting a bound antibody. In this case, an antibody having higher reaction specificity can be produced.
  • the above antigenic protein may be a membrane protein.
  • an anti-membrane protein antibody can be produced.
  • the above antigenic protein may be a membrane protein which forms a dimer.
  • an antibody binding to a membrane protein which forms a dimer can be produced.
  • the dimer includes a heterodimer or a homodimer.
  • the above antigenic protein may be an integrin a8 chain or integrin ⁇ 8 ⁇ 1.
  • the above antibody may be an anti-integrin ⁇ 8 ⁇ 1 antibody.
  • an anti-integrin ⁇ 8 ⁇ 1 antibody that inhibits the binding between integrin ⁇ 8 ⁇ 1 and its ligand can be produced.
  • an anti-integrin ⁇ 8 ⁇ 1 antibody that binds to integrin ⁇ 8 ⁇ 1 derived from any of a human and a mouse can be produced.
  • an anti-integrin ⁇ 8 ⁇ 1 antibody that recognizes a site different from a site in the case of using a recombinant soluble integrin ⁇ 8 ⁇ 1 as an antigen can be produced.
  • the recombinant soluble integrin include a recombinant fusion protein between an integrin a8 chain and/or integrin ⁇ 1 chain and an Fc region of an antibody.
  • the production process including the step of immunizing a mouse, etc., a species taxonomically related to a human, has become mainstream.
  • the above production process includes the step of immunizing a chicken, a species taxonomically far from a human.
  • the above production process has a feature distinct from that of the production process which has previously become main stream. Accordingly, in the case of using the above production process, an antibody having a structure different from that of an antibody generated from a mammal such as a mouse can be produced.
  • the above antibody or inhibitor can be suitably used as a therapeutic or diagnostic agent for the above diseases (e.g., cancer, arthritis, glaucoma, or neuropathic pain).
  • the ligand for integrin ⁇ 8 ⁇ 1 is not limited as long as the ligand is a substance interacting with integrin ⁇ 8 ⁇ 1.
  • the ligand is preferably fibronectin, vitronectin, tenascin, or osteopontin. It is well known that they interact with integrin ⁇ 8 ⁇ 1. Also, the subsequent integrin ⁇ 8 ⁇ 1-mediated intracellular signal transduction mechanism is relatively better elucidated.
  • osteopontin is preferable. This is because osteopontin plays a critical role in diverse physiological effects so that it is an important molecule for development of a therapeutic agent etc. For example, osteopontin is involved in functions such as cell adhesion, cell migration, tumorigenesis, and immune responses. It is reported that its inhibition in vivo results in a therapeutic effect on arthritis ( JP4064441B ).
  • binding inhibition effects can be measured by any method known in the art, such as an ELISA, FACS analysis, and a BIACORE method. The results may be measured that the above anti-integrin ⁇ 8 ⁇ 1 antibody competitively inhibits the binding in the presence of both integrin ⁇ 8 ⁇ 1 and its ligand. Alternatively, the modes of the binding of the above anti-integrin ⁇ 8 ⁇ 1 antibody to integrin ⁇ 8 ⁇ 1 may be determined as an index for inhibition of binding between integrin ⁇ 8 ⁇ 1 and its ligand. The measurements of the binding inhibition effects are preferably determined by a method described in the Examples below.
  • the FACS analysis typically includes the steps of: irradiating a cell flowing inside a flow cell with a laser beam; measuring parameters as obtained from forward-scattered light and side-scattered light; and determining cellular properties.
  • An amount of a fluorescence-labeled antibody binding to one cell is proportional to an amount of a surface antigen on the cell.
  • the fluorescence intensity is proportional to the amount of the surface antigen.
  • modes of binding of the above anti-integrin ⁇ 8 ⁇ 1 antibody to integrin ⁇ 8 ⁇ 1 can be represented by a dissociation constant (KD), an association constant (Ka), an association rate constant (ka), and a dissociation rate constant (kd).
  • KD dissociation constant
  • Ka association constant
  • ka association rate constant
  • kd dissociation rate constant
  • the ELISA can be implemented with a relatively low cost, and is the most common technique.
  • the ELISA is an assay for determining a specific interaction, including: immobilizing, on a microplate, a predetermined amount of an antigen or antibody specifically reacting with a substance of measurement subject; adding the substance of measurement subject and an enzymatically labeled antigen together to react them; and measuring an enzymatic activity of the enzymatically labeled antigen bound to the microplate by using a colorimetric method or a fluorescence method.
  • the assay utilizes a high binding capability and molecule-recognition capability of an antibody, so that detection can be achieved with very high sensitivity, compared with HPLC etc.
  • the BIACORE system is an excellent measurement method which can determine a dynamic parameter.
  • the method includes: immobilizing a biomolecule on a sensor surface; applying an interaction partner molecule; and carrying out a real-time measurement of a specific interaction on the sensor surface. Without the need for labeling molecules, the BIACORE system can measure in real-time a specific interaction from an association reaction to an equilibrium state and a dissociation reaction. Measurement manipulations include: immobilizing a ligand on a sensor surface; applying a sample solution containing a reaction substance into a microchannel system; and measuring a specific interaction occurring on the sensor surface as a small mass change.
  • the measurement principle employs an optical phenomenon, what is called surface plasmon resonance (SPR), so that a reliable measurement can be carried out.
  • SPR surface plasmon resonance
  • association rate constant (ka) and a dissociation rate constant (kd) can be calculated based on reaction rates directly obtained, which allows for detailed analysis ( Jonsson et al., Biotechniques, 1991, Nov., 11(5), 620-7 ; Fivash et al., Curr Opin Biotechnol., 1998, Feb., 9(1), 97-101 ; " Experiment Handbook of Instrumental Analysis for Life Science", YODOSHA CO., LTD., 2007, 243-248 ).
  • strength of inhibition of binding between integrin ⁇ 8 ⁇ 1 and its ligand by an anti-integrin ⁇ 8 ⁇ 1 antibody can be evaluated by, for example, the following procedure. First, an anti-integrin ⁇ 8 ⁇ 1 antibody is reacted with integrin ⁇ 8 ⁇ 1-expressing cells. Next, the integrin ⁇ 8 ⁇ 1-expressing cells after the reaction are made to react with osteopontin. Finally, the number of the integrin ⁇ 8 ⁇ 1-expressing cells bound to osteopontin is determined by absorbance at 570 nm, and this procedure can thus evaluate the strength.
  • absorbance as obtained in a negative control experiment can be set to a reference value which is designated as 0% of the binding inhibition strength.
  • absorbance at the time of using cells which do not express integrin ⁇ 8 ⁇ 1, instead of using the integrin ⁇ 8 ⁇ 1-expressing cells can be set to a reference value which is designated as 100% of the binding inhibition strength.
  • the binding inhibition strength of the above anti-integrin ⁇ 8 ⁇ 1 antibody is, but not particularly limited to, for example, 5, 25, 50, 75, 95, or 100%.
  • This binding inhibition strength may be any one of the above values or higher, or may be between any two of the above values.
  • the above activity of binding of an anti-integrin ⁇ 8 ⁇ 1 antibody to integrin ⁇ 8 ⁇ 1 can be estimated by FACS analysis and by calculating, as a positive rate, a ratio of the number of cells reacted with the test antibody to the total number of cells.
  • This positive rate is, but not particularly limited to, for example, 5, 25, 50, 75, 95, or 100%.
  • This positive rate may be any one of the above values or higher, or may be between any two of the above values.
  • treatment refers to exerting a prophylactic effect or a symptom-improving effect on a disease of a subject individual or on one or more symptoms involving the disease.
  • Fibrosis refers to a symptom in which a tissue is damaged by some reason and becomes fibrous.
  • the fibrosis include pulmonary fibrosis, hepatic fibrosis, myelofibrosis, cystic fibrosis, mammary gland fibrosis, and the like.
  • the examples further include diseases that are classified into fibrosis-related diseases reported (in ICD10 international classification of disease, the 10th edition) by World Health Organization (WHO).
  • Renal failure refers to a symptom in which kidney functions decrease and the kidney no longer functions normally.
  • the renal failure is largely classified into acute renal failure and chronic renal failure.
  • the chronic renal failure is a disease in which renal function damage chronically progresses.
  • Examples of the chronic renal failure include those responsible for progression of chronic glomerulonephritis, diabetes mellitus, glomerulosclerosis, or interstitial fibrosis.
  • Examples of the acute renal failure include prerenal acute renal failure, renal acute renal failure, postrenal acute renal failure, and the like.
  • the examples further include those caused by allergy, toxicity, glomerular dysfunction, or tubulointerstitial disorder.
  • Inner ear disease includes a diseases resulting from disorders in organs, tissues, or nerves constituting an inner ear.
  • Examples of the inner ear disease include labyrinthitis, Meniere's disease, diseases caused by a drug such as aspirin, hearing loss, streptomycin deafness, and the like.
  • the examples further include diseases that are classified into inner ear-related diseases (in ICD10 international classification of disease, the 10th edition).
  • Arthritis refers to a joint inflammation-mediated disease having various symptoms such as pain, swelling, and heat.
  • arthritis include gouty arthritis, rheumatoid arthritis, psoriatic arthritis, osteochondritis dissecans, a knee disease, idiopathic osteonecrosis, deformans arthritis, septic arthritis, tuberculosis arthritis, hydrarthrosis, and the like.
  • the examples further include diseases that are classified into arthritis-related diseases (in ICD10 international classification of disease, the 10th edition).
  • Cancer refers to a disease in which a normal cell is mutated and continues proliferation.
  • a malignant cancer cell is generated from any organ or tissue in the body. Once the cancer cell proliferates, a solid consisting of the cancer tissue infiltrates into and destroys a surrounding normal tissue.
  • the cancer include breast cancer, colorectal cancer, lung cancer, prostate cancer, hepatocarcinoma, gastric cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, ureteric cancer, thyroid cancer, kidney cancer, carcinoma, melanoma, brain tumor, and the like.
  • Glaucoma refers to an eye disease in which an increase in an intraocular pressure causes deficiency of a visual field.
  • Examples of the glaucoma include primary glaucoma, congenital glaucoma, secondary glaucoma, and the like.
  • the examples further include diseases that are classified into glaucoma-related diseases (in ICD10 international classification of disease, the 10th edition).
  • Neuropathic pain refers to pain resulting from primary damage or dysfunction of a nervous system or pain caused thereby.
  • Examples of the neuropathic pain include postherpetic neuralgia, pain after cerebral infarction, low back pain, postoperative chronic pain, and the like.
  • the examples further include those based on a neuropathic pain mechanism or a noxious pain mechanism.
  • the above anti-integrin ⁇ 8 ⁇ 1 antibody or the inhibitor, which contains the above anti-integrin ⁇ 8 ⁇ 1 antibody, of binding between integrin ⁇ 8 ⁇ 1 and its ligand can be used as a therapeutic or prophylactic agent. In that case, sole administration may be allowed. However, one or more pharmaceutically acceptable carriers are usually mixed together. Then, it is preferable to provide a pharmaceutical preparation that is produced by any of the methods well known in the art of pharmaceutics. Alternatively, without directly using the above anti-integrin ⁇ 8 ⁇ 1 antibody, a polynucleotide encoding the above anti-integrin ⁇ 8 ⁇ 1 antibody or a vector thereof can be administered.
  • an administration route at the time of in vivo administration of the above anti-integrin ⁇ 8 ⁇ 1 antibody the most effective one for treatment is preferably used.
  • the administration route include oral administration and parenteral administration such as intraoral, tracheobronchial, endorectal, subcutaneous, intramuscular, intraocular, and intravenous administration.
  • systemic or topical administration may be allowed.
  • the administration route may be preferably intravenous administration.
  • Examples of an additional dosage form can include sprays, capsules, tablets, granules, syrups, emulsions, suppositories, injections, ointments, tapes, and the like.
  • Examples of the formulation suitable for oral administration can include emulsions, syrups, capsules, tablets, powder medicines, granules, and the like.
  • Liquid preparations such as emulsions and syrups can be prepared using additives including water, sugars (e.g., sucrose, sorbitol, fructose), glycols (e.g., polyethylene glycol, propylene glycol), oils (e.g., a sesame oil, an olive oil, a soy oil), preservatives (e.g., p-hydroxy benzoate esters), flavors (e.g., strawberry flavor, peppermint), and/or the like.
  • sugars e.g., sucrose, sorbitol, fructose
  • glycols e.g., polyethylene glycol, propylene glycol
  • oils e.g., a sesame oil, an olive oil, a soy oil
  • preservatives e.g., p-hydroxy benzoate esters
  • flavors e.g., strawberry flavor, peppermint
  • the capsules, tablets, powder medicines, or granules can be prepared using additives including excipients (e.g., lactose, glucose, sucrose, mannitol), disintegrants (e.g., starch, sodium alginate), lubricants (e.g., magnesium stearate, talc), binders (e.g., polyvinyl alcohol, hydroxypropylcellulose, gelatin), surfactants (e.g., fatty acid ester), plasticizers (e.g., glycerol), and/or the like.
  • excipients e.g., lactose, glucose, sucrose, mannitol
  • disintegrants e.g., starch, sodium alginate
  • lubricants e.g., magnesium stearate, talc
  • binders e.g., polyvinyl alcohol, hydroxypropylcellulose, gelatin
  • surfactants e.g., fatty acid ester
  • Examples of the formulation suitable for parenteral administration can include injections, suppositories, sprays, and the like.
  • an aqueous solution used for injections can include a saline and an isotonic solution containing glucose or another adjuvant such as D-sorbitol, D-mannose, D-mannitol, and sodium chloride.
  • the adjuvant can be combined with a solubilization aid (e.g., alcohol (e.g., ethanol)), polyalcohol (e.g., propylene glycol, polyethylene glycol), and/or a non-ionic surfactant (e.g., polysorbate 80 (TM), HCO-50).
  • a solubilization aid e.g., alcohol (e.g., ethanol)
  • polyalcohol e.g., propylene glycol, polyethylene glycol
  • TM non-ionic surfactant
  • the suppositories may be prepared using a carrier such as cacao butter, hydrogenated fat, or carboxylic acid.
  • the sprays may be prepared using the inhibitor of binding between integrin ⁇ 8 ⁇ 1 and its ligand and using a carrier, etc., which does not stimulate an oral cavity and respiratory tract mucosa of recipients and which makes the inhibitor of binding between integrin ⁇ 8 ⁇ 1 and its ligand disperse as fine particles, so that the inhibitor is absorbed easily.
  • this carrier include lactose, glycerol, and the like.
  • Formulations such as aerosol and dry powder are allowed depending on characteristics of the carrier used and the inhibitor of binding between integrin ⁇ 8 ⁇ 1 and its ligand.
  • the components exemplified as additives for oral agents can be added to even these parenteral agents.
  • the above prophylactic or therapeutic agent may be formulated with buffers (e.g., a phosphate buffer, a sodium acetate buffer), soothing agents (e.g., benzalkonium chloride, procaine hydrochloride), stabilizers (e.g., human serum albumin, polyethylene glycol), preservatives (e.g., benzyl alcohol, phenol), antioxidants, and/or the like.
  • buffers e.g., a phosphate buffer, a sodium acetate buffer
  • soothing agents e.g., benzalkonium chloride, procaine hydrochloride
  • stabilizers e.g., human serum albumin, polyethylene glycol
  • preservatives e.g., benzyl alcohol, phenol
  • antioxidants e.g., benzyl alcohol, phenol
  • Prepared injections are usually filled in suitable ampules.
  • Formulations as obtained in such a manner are safe and less toxic. Accordingly, the formulations can
  • an administration procedure can be appropriately selected depending on an age, a symptom, an affected organ, etc., of a patient.
  • the dose of a pharmaceutical composition containing the above anti-integrin ⁇ 8 ⁇ 1 antibody or a polynucleotide encoding the above anti-integrin ⁇ 8 ⁇ 1 antibody can be selected from, for example, a range between 0.0001 mg and 1000 mg per kg body weight.
  • the dose can be selected from, but is not necessarily limited to, a range between 0.001 and 100000 mg per patient body.
  • the dose per kg body weight is, for example, 0.0001, 0.01, 1, 50, 100, 250, 500, or 1000 mg. This dose may be within a range between any two values indicated herein.
  • the dose is different depending on an intended therapeutic effect, an administration procedure, a treatment period, an age, a body weight, or the like.
  • the dose and administration procedure vary depending on a body weight, an age, and a symptom, etc. of a patient. However, those skilled in the art can appropriately select them.
  • the administration may be combined with a suitable chemotherapeutic agent.
  • a therapeutic objective resides in the brain and a therapeutic agent is required to pass through the blood-brain barrier (BBB)
  • BBB blood-brain barrier
  • the above anti-integrin ⁇ 8 ⁇ 1 antibody may be modified into a form which allows for passage through the BBB.
  • a method known in the art can be used.
  • Examples of the method can include a method for extending gaps in the BBB, a method for using a membrane protein expressed in the BBB, a CED (convection-enhanced delivery) method, and the like (see a review by Bidros et al., Neurotherapeutics, 2009, Jul., 6(3), 539-46 ).
  • This diagnostic agent contains the above anti-integrin ⁇ 8 ⁇ 1 antibody, so that the diagnostic agent can be suitably used for diagnosis of various diseases involving integrin ⁇ 8 ⁇ 1.
  • usage of the diagnostic agent is not particularly limited.
  • diagnosis of the above diseases seems to be executed by examining and comparing the modes of binding of the antibody to integrin ⁇ 8 ⁇ 1 between standard cells, etc., and materials such as cells, blood, serum, body fluid, or pathologic sections of any of the above diseases.
  • the binding level of the antibody increases.
  • competition with the ligand causes the binding level of the antibody to decrease. Because of this, this diagnostic agent can achieve an effect of diagnosing the above diseases.
  • Examples of a detection method at the time of using the antibody as a diagnostic agent can herein include, but are not limited to, a radioimmunoassay, an enzyme immunoassay, a fluoroimmunoassay, a luminescence immunoassay, immunoprecipitation, immune nephelometry, and the like.
  • the enzyme immunoassay is preferable. Particularly preferred is an ELISA (e.g., a sandwich ELISA).
  • the above immunological method such as an ELISA can be carried out using a procedure known to those skilled in the art.
  • the diagnostic agent includes a reagent for PET (Positron Emission Tomography), or a reagent or material used for experiments.
  • a typical detection method using the above anti-integrin ⁇ 8 ⁇ 1 antibody can include: immobilizing the above anti-integrin ⁇ 8 ⁇ 1 antibody on a support; adding a test sample thereto; incubating them; causing the above anti-integrin ⁇ 8 ⁇ 1 antibody to bind to integrin ⁇ 8 ⁇ 1, a recipient, in the test sample, and thereafter; washing them; detecting the integrin ⁇ 8 ⁇ 1 binding to the support via the above anti-integrin ⁇ 8 ⁇ 1 antibody, thereby detecting the integrin ⁇ 8 ⁇ 1 in the test sample.
  • Examples of a preferable embodiment of detection of integrin ⁇ 8 ⁇ 1, a recipient, binding to a support via the above anti-integrin ⁇ 8 ⁇ 1 antibody can include a method using a labeled-substance-labeled anti-integrin ⁇ 8 ⁇ 1 antibody. For example, a test sample is made to contact the above anti-integrin ⁇ 8 ⁇ 1 antibody immobilized on a support. After washing, a labeled-substance-labeled anti-integrin ⁇ 8 ⁇ 1 antibody is made to contact the test sample. Then, the labeled substance is detected using another labeled antibody to create an index for the integrin ⁇ 8 ⁇ 1.
  • the labeling of the above anti-integrin ⁇ 8 ⁇ 1 antibody can be performed using a commonly known procedure.
  • the labeled substance which can be used include labeled substances known to those skilled in the art, such as fluorescent dye, an enzyme, a coenzyme, a chemiluminescent substance, and a radioactive material.
  • the labeled substance can include a radioisotope (e.g., 32 P, 14 C, 125 I, 3 H, 131 I), fluorescein, rhodamine, dansyl chloride, umbelliferone, luciferase, peroxidase, alkaline phosphatase, ⁇ -galactosidase, ⁇ -glucosidase, horseradish peroxidase, glucoamylase, lysozyme, saccharide oxidase, microperoxidase, biotin, and the like.
  • a biotin-labeled antibody is added.
  • avidin which is conjugated to an enzyme such as alkaline phosphatase is then further added.
  • a reagent comprising the above anti-integrin ⁇ 8 ⁇ 1 antibody as defined in the claims or a reagent comprising an inhibitor of binding between integrin ⁇ 8 ⁇ 1 and its ligand, the inhibitor containing the above anti-integrin ⁇ 8 ⁇ 1 antibody as defined in the claims.
  • the reagent contains a material, etc., for basic research, and can be used for, for example, an ELISA, Western blotting, or FACS analysis. Applications of this reagent can be used for, but are not particularly limited to, measurements of an expression level of integrin ⁇ 8 ⁇ 1 in a living tissue.
  • the applications may come with an instruction which describes usage and examples at the time of using the reagent, a document indicating where the instruction can be obtained, and/or various buffers.
  • cross-reactivity generally refers to a characteristic in which a certain antibody has a significant binding affinity for any of two or more antigens having a similar structure.
  • antigens having a similar structure include a protein having high homology.
  • An embodiment of the present invention provides an anti-integrin ⁇ 8 ⁇ 1 antibody as defined in the claims which inhibits binding between integrin ⁇ 8 ⁇ 1 and its ligand.
  • this anti-integrin ⁇ 8 ⁇ 1 antibody is used, the binding between integrin ⁇ 8 ⁇ 1 and its ligand can be inhibited.
  • various functions such as integrin ⁇ 8 ⁇ 1-mediated signal transduction can also be inhibited.
  • a therapeutic or diagnostic agent for diseases involving integrin ⁇ 8 ⁇ 1 can be obtained.
  • the above ligand may be osteopontin, fibronectin, tenascin, or vitronectin.
  • various functions such as signal transduction involving the binding between integrin ⁇ 8 ⁇ 1 and osteopontin, etc., can be inhibited.
  • a therapeutic or diagnostic agent for diseases involving the binding between integrin ⁇ 8 ⁇ 1 and osteopontin, etc. can be obtained.
  • the above ligand may be osteopontin.
  • various functions can be inhibited which relate to signal transduction involving binding between integrin a 8 ⁇ 1 and osteopontin (this binding has a particular importance during development of a therapeutic agent etc).
  • a therapeutic or diagnostic agent for diseases involving the binding between integrin ⁇ 8 ⁇ 1 and osteopontin can be obtained.
  • the above anti-integrin ⁇ 8 ⁇ 1 antibodies may include an anti-integrin ⁇ 8 ⁇ 1 antibody which also binds to integrin ⁇ 8 ⁇ 1 derived from mammals of different species.
  • use of the above anti-integrin ⁇ 8 ⁇ 1 antibody can inhibit various functions such as integrin ⁇ 8 ⁇ 1-mediated signal transduction in mammals.
  • a therapeutic or diagnostic agent for mammalian diseases involving integrin ⁇ 8 ⁇ 1 can be obtained.
  • the above anti-integrin ⁇ 8 ⁇ 1 antibody can be suitably used as a component of an agent (e.g., a therapeutic agent) which is important to examine its effect on multiple organisms.
  • the above anti-integrin ⁇ 8 ⁇ 1 antibodies may include an anti-integrin ⁇ 8 ⁇ 1 antibody which binds to integrin ⁇ 8 ⁇ 1 derived from any of a human and a mouse.
  • an anti-integrin ⁇ 8 ⁇ 1 antibody which binds to integrin ⁇ 8 ⁇ 1 derived from any of a human and a mouse.
  • a therapeutic or diagnostic agent containing the above anti-integrin ⁇ 8 ⁇ 1 antibody can be used for a human and a mouse.
  • a model mouse can be used.
  • the above anti-integrin ⁇ 8 ⁇ 1 antibody may be an antibody which binds to an integrin a8 chain.
  • the integrin a8 chain forms a heterodimer only with a ⁇ 1 chain.
  • the above anti-integrin a8 antibody can bind to integrin ⁇ 8 ⁇ 1.
  • use of the above anti-integrin ⁇ 8 ⁇ 1 antibody can inhibit the binding between integrin ⁇ 8 ⁇ 1 and its ligand.
  • the above anti-integrin ⁇ 8 ⁇ 1 antibody may be a monoclonal antibody.
  • the above anti-integrin ⁇ 8 ⁇ 1 antibody can recognize integrin ⁇ 8 ⁇ 1 with high specificity, thereby efficiently binding to integrin ⁇ 8 ⁇ 1. Also, the binding between integrin ⁇ 8 ⁇ 1 and its ligand can be efficiently inhibited.
  • the above anti-integrin ⁇ 8 ⁇ 1 antibodies may include one or more anti-integrin ⁇ 8 ⁇ 1 antibodies selected from the group consisting of chicken antibodies, chimeric antibodies, humanized antibodies, and human antibodies.
  • the above anti-integrin ⁇ 8 ⁇ 1 antibodies contain a humanized amino acid sequence.
  • immunogenicity against a human can be decreased.
  • the above anti-integrin ⁇ 8 ⁇ 1 antibodies may bind to wild type or mutant integrin ⁇ 8 ⁇ 1.
  • the above anti-integrin ⁇ 8 ⁇ 1 antibodies can bind to integrin ⁇ 8 ⁇ 1 having an amino acid sequence different from that of the wild type. Also, it is possible to inhibit the binding between integrin ⁇ 8 ⁇ 1 having an amino acid sequence different from that of the wild type and its ligand.
  • the above anti-integrin ⁇ 8 ⁇ 1 antibodies may be an antibody fragment.
  • the above anti-integrin ⁇ 8 ⁇ 1 antibodies are shorter than an entire antibody, so that their in vivo administration decreases immunogenicity.
  • the in vivo administration can increase their stability, or an effect of increasing an antibody production efficiency, etc., can be achieved.
  • this antibody fragment contains a functional portion of the above anti-integrin ⁇ 8 ⁇ 1 antibodies.
  • the antibody fragment may comprise heavy chain CDR1 to CDR3, or light chain CDR1 to CDR3.
  • Another embodiment of the present invention provides a polynucleotide comprising a nucleotide sequence encoding the above anti-integrin ⁇ 8 ⁇ 1 antibody as defined in the claims.
  • the above anti-integrin ⁇ 8 ⁇ 1 antibody can be produced by using a procedure known in the art.
  • the above anti-integrin ⁇ 8 ⁇ 1 antibody can be produced by using a procedure known in the art.
  • an inhibitor of binding between integrin ⁇ 8 ⁇ 1 and its ligand comprising the above anti-integrin ⁇ 8 ⁇ 1 antibody as defined in the claims. If this inhibitor of binding between integrin ⁇ 8 ⁇ 1 and its ligand is used, various functions such as integrin ⁇ 8 ⁇ 1-mediated signal transduction can be inhibited. Also, a therapeutic or diagnostic agent for diseases involving integrin ⁇ 8 ⁇ 1 can be obtained.
  • a therapeutic agent comprising the above anti-integrin ⁇ 8 ⁇ 1 antibody as defined in the claims, wherein the agent is used for one or more diseases selected from the group consisting of cancer, arthritis, glaucoma, and neuropathic pain.
  • this therapeutic agent is used, an effect of treating the above diseases can be achieved.
  • this therapeutic agent may be a therapeutic agent for the above diseases in mammals.
  • this therapeutic agent when used, an effect of treating the above diseases in mammals can be obtained.
  • a diagnostic agent comprising the above anti-integrin ⁇ 8 ⁇ 1 antibody as defined in the claims, wherein the diagnostic agent is used for one or more diseases selected from the group consisting of pulmonary fibrosis, hepatic fibrosis, renal failure, inner ear disease, tumor, arthritis, glaucoma, and neuropathic pain.
  • the above anti-integrin ⁇ 8 ⁇ 1 antibody can achieve an effect of diagnosing the above diseases.
  • this diagnostic agent may be a diagnostic agent for the above diseases in mammals.
  • this diagnostic agent can achieve an effect of diagnosing the above diseases in mammals.
  • a reagent comprising the above anti-integrin ⁇ 8 ⁇ 1 antibody as defined in the claims.
  • use of the above reagent allows for application to experiments (e.g., an ELISA) involving integrin ⁇ 8 ⁇ 1, investigation of the localization of integrin ⁇ 8 ⁇ 1 in mammalian tissues or cells, or the like.
  • Another embodiment of the present invention provides an anti-integrin ⁇ 8 ⁇ 1 antibody as defined in the claims which binds to integrin ⁇ 8 ⁇ 1 derived from mammals of different species.
  • this anti-integrin ⁇ 8 ⁇ 1 antibody is used, it is possible to examine the localization of integrin ⁇ 8 ⁇ 1 in mammalian tissues or cells etc.
  • the above anti-integrin ⁇ 8 ⁇ 1 antibodies can be used for mammals of different species.
  • these anti-integrin ⁇ 8 ⁇ 1 antibodies may include an anti-integrin ⁇ 8 ⁇ 1 antibody which binds to integrin ⁇ 8 ⁇ 1 derived from any of a human and a mouse.
  • an anti-integrin ⁇ 8 ⁇ 1 antibody which binds to integrin ⁇ 8 ⁇ 1 derived from any of a human and a mouse.
  • the anti-integrin ⁇ 8 ⁇ 1 antibodies when used, it is possible to examine the localization of integrin ⁇ 8 ⁇ 1 in tissues or cells affected by human and mouse diseases.
  • the above anti-integrin ⁇ 8 ⁇ 1 antibodies can be used for a human and a mouse.
  • a model mouse can be used.
  • these anti-integrin ⁇ 8 ⁇ 1 antibodies may include an antibody which binds to an integrin a8 chain.
  • the integrin a8 chain forms a heterodimer only with a ⁇ 1 chain. Consequently, the above anti-integrin a8 antibody can bind to integrin ⁇ 8 ⁇ 1. Because of this, when the above anti-integrin ⁇ 8 ⁇ 1 antibody is used, it is possible to examine the localization of an integrin a8 chain and integrin ⁇ 8 ⁇ 1 in mammalian tissues or cells etc.
  • integrin ⁇ 8 ⁇ 1 antibodies are used as a therapeutic or diagnostic agent comprising the above anti-integrin ⁇ 8 ⁇ 1 antibody, integrin ⁇ 8 ⁇ 1 can be used as their target.
  • this anti-integrin ⁇ 8 ⁇ 1 antibody may be a monoclonal antibody.
  • the above anti-integrin ⁇ 8 ⁇ 1 antibody can recognize integrin ⁇ 8 ⁇ 1 with high specificity, thereby efficiently binding to integrin ⁇ 8 ⁇ 1.
  • this anti-integrin ⁇ 8 ⁇ 1 antibody is used to inhibit the binding between integrin ⁇ 8 ⁇ 1 and its ligand, its inhibition efficiency increases.
  • Another embodiment of the present invention provides a polynucleotide comprising a nucleotide sequence encoding an anti-integrin ⁇ 8 ⁇ 1 antibody as defined in the claims which binds to integrin ⁇ 8 ⁇ 1 derived from mammals of different species.
  • the above anti-integrin ⁇ 8 ⁇ 1 antibody can be produced by using a procedure known in the art.
  • a vector comprising a polynucleotide or a portion thereof, the polynucleotide containing a nucleotide sequence encoding an anti-integrin ⁇ 8 ⁇ 1 antibody as defined in the claims which binds to integrin ⁇ 8 ⁇ 1 derived from mammals of different species.
  • the above anti-integrin ⁇ 8 ⁇ 1 antibody can be produced by using a procedure known in the art.
  • an inhibitor of binding between integrin ⁇ 8 ⁇ 1 and its ligand comprising an anti-integrin ⁇ 8 ⁇ 1 antibody as defined in the claims which binds to integrin ⁇ 8 ⁇ 1 derived from mammals of different species. If this inhibitor of binding between integrin ⁇ 8 ⁇ 1 and its ligand is used, various functions such as integrin ⁇ 8 ⁇ 1-mediated signal transduction can be inhibited. Also, a therapeutic or diagnostic agent for diseases involving integrin ⁇ 8 ⁇ 1 can be obtained.
  • a therapeutic agent comprising an anti-integrin ⁇ 8 ⁇ 1 antibody as defined in the claims which binds to integrin ⁇ 8 ⁇ 1 derived from mammals of different species, wherein the therapeutic agent is used for one or more diseases selected from the group consisting of cancer, arthritis, glaucoma, and neuropathic pain.
  • this therapeutic agent is used, an effect of treating the above diseases can be achieved.
  • this therapeutic agent may be a therapeutic agent for the above diseases in mammals.
  • this therapeutic agent when used, an effect of treating the above diseases in mammals can be obtained.
  • a diagnostic agent comprising an anti-integrin ⁇ 8 ⁇ 1 antibody as defined in the claims which binds to integrin ⁇ 8 ⁇ 1 derived from mammals of different species, wherein the diagnostic agent is used for one or more diseases selected from the group consisting of pulmonary fibrosis, hepatic fibrosis, renal failure, inner ear disease, tumor, arthritis, glaucoma, and neuropathic pain.
  • the diagnostic agent is used for one or more diseases selected from the group consisting of pulmonary fibrosis, hepatic fibrosis, renal failure, inner ear disease, tumor, arthritis, glaucoma, and neuropathic pain.
  • use of the above anti-integrin ⁇ 8 ⁇ 1 antibody can achieve an effect of diagnosing the above diseases.
  • this diagnostic agent may be a diagnostic agent for the above diseases in mammals.
  • this diagnostic agent can achieve an effect of diagnosing the above diseases in mammals.
  • a reagent comprising an anti-integrin ⁇ 8 ⁇ 1 antibody as defined in the claims which binds to integrin ⁇ 8 ⁇ 1 derived from mammals of different species.
  • use of the above reagent allows for application to experiments (e.g., an ELISA) involving integrin ⁇ 8 ⁇ 1, investigation of the localization of integrin ⁇ 8 ⁇ 1 in mammalian tissues or cells, or the like.
  • Another aspect of the present disclosure provides a process for producing an anti-integrin ⁇ 8 ⁇ 1 antibody as defined in the claims, the process comprising the step of immunizing a chicken with an antigen containing an integrin a8 chain. If this production process is used, it is possible to obtain an anti-integrin ⁇ 8 ⁇ 1 antibody which inhibits binding between integrin ⁇ 8 ⁇ 1 and its ligand or an anti-integrin ⁇ 8 ⁇ 1 antibody which binds to integrin ⁇ 8 ⁇ 1 derived from mammals of different species. In addition, it is possible to obtain an inhibitor of binding between integrin ⁇ 8 ⁇ 1 and its ligand, the inhibitor comprising an anti-integrin ⁇ 8 ⁇ 1 antibody.
  • Example 1 Production of Mouse Integrin ⁇ 8-Expressing Chicken Cell Line and Immunization of Chicken Therewith>
  • the cDNA of a mouse integrin a8 chain was cloned into a mammalian expression vector.
  • the expression vector was transfected into a chicken lymphoblastoid cell line by electroporation.
  • an antibiotic was added, and vector-expressing cells were selected.
  • a chicken was hyperimmunized with the resulting mouse integrin ⁇ 8-expressing cells.
  • the antibody titer was determined by flow cytometry (FACS) analysis.
  • the FACS analysis was performed in accordance with a typical protocol of FACSCalibur (BD, USA). It is known that an integrin a8 chain forms a heterodimer with a ⁇ 1 chain ( Luo et al., Annu Rev Immunol., 2007, 25, 619-47 ).
  • an antibody as obtained by immunizing a chicken with the mouse integrin ⁇ 8-expressing cells recognizes integrin ⁇ 8 ⁇ 1, and can be used as an anti-integrin ⁇ 8 ⁇ 1 antibody.
  • the scFv phage library was added to mouse integrin a8 expression-free cells, and non-specific phages were adsorbed. Next, the resulting library was reacted with the mouse integrin ⁇ 8-expressing cells. The mixture was washed with an organic solvent. Then, phages which had bound to the mouse integrin ⁇ 8-expressing cells were collected, and Escherichia coli bacteria were infected therewith. After panning was performed four times, the library reactivity was examined by FACS analysis using the mouse integrin ⁇ 8-expressing cells. Since the third library had high reactivity, cloning of phages was carried out from the third library. After selection of positive clones, their sequences were determined. The cell panning was performed according to a procedure described in Giordano et al., Nat Med., 2001, Nov., 7(11), 1249-53 .
  • a human integrin ⁇ 8-expressing chicken lymphoblastoid cell line was produced. Clones which had been cross-reacted with the human integrin ⁇ 8-expressing cell line were selected by FACS.
  • chicken antibody genes of V H and V L were amplified by PCR.
  • the overlap PCR of a leader sequence and a constant region of the chicken antibody gene was carried out, and they were cloned into an rIgY-expressing vector.
  • the prepared H-chain and L-chain constructs were transfected into mammalian cultured cells. After that, an expressed antibody protein was purified.
  • Engineering of the rIgY antibody was performed in accordance with a typical procedure described in Shimamoto et al., Biologicals, 2005, Sep., 33(3), 169-74 .
  • FIG. 4 shows the results.
  • the peak positions of the three kinds of the anti-integrin ⁇ 8 ⁇ 1 chicken monoclonal antibody were clearly shifted to the right side, compared with those observed at the time of using non-expressing cells. This demonstrates that those antibodies can bind to integrin ⁇ 8 ⁇ 1 derived from both a human and a mouse.
  • Respective plasmids containing a DNA sequence encoding a heavy chain of the anti-integrin ⁇ 8 ⁇ 1 chicken monoclonal antibodies were domestically deposited at Biological Resource Center, National Institute of Technology and Evaluation (Kazusa Kamatari 2-5-8, Kisarazu-city, Chiba) on October 16, 2009. After that, the above domestically deposited plasmids were changed to international deposition as Accession No: NITE BP-824, Accession No: NITE BP-826, and Accession No: NITE BP-828, respectively, under the Budapest Treaty on October 12, 2010.
  • Respective plasmids containing a DNA sequence encoding a light chain of the anti-integrin ⁇ 8 ⁇ 1 chicken monoclonal antibodies were domestically deposited at Biological Resource Center, National Institute of Technology and Evaluation on October 16, 2009. After that, the above domestically deposited plasmids were changed to international deposition as Accession No: NITE BP-825, Accession No: NITE BP-827, and Accession No: NITE BP-829, respectively, under the Budapest Treaty on October 12, 2010. It is notable that those six deposited plasmids were constructed using the same expression vector as in the above (5-1).
  • amino acid sequences of the heavy chain CDRs and the light chain CDRs of the above anti-integrin ⁇ 8 ⁇ 1 chicken monoclonal antibodies were examined.
  • Table 1 shows the results.
  • the "X” denotes an amino acid which was unable to be analyzed by amino acid analysis.
  • Anti-integrin ⁇ 8 ⁇ 1 antibodies which bound to integrin ⁇ 8 ⁇ 1 derived from any of a human and a mouse were obtained. Use of these antibodies enables the localization of integrin ⁇ 8 ⁇ 1 to be investigated in normal and disease-related tissues or cells, etc., in a human. Further, the present antibody cross-reacts with mouse integrin ⁇ 8 ⁇ 1, so that the localization of integrin ⁇ 8 ⁇ 1 can be investigated in a model mouse. Accordingly, the present antibody can be suitably used as a material to acquire basic information on application to a human.
  • Mouse osteopontin (2.5 ⁇ g/ml) was immobilized on a 96-well plate, and integrin ⁇ 8-expressing K562 cells were added thereto at 1 x 10E5 cells/well.
  • the above No.3, No.5, or No.26 antibody was also added at the concentration designated in FIG. 5 , and it was examined how much the antibody inhibited adhesion of cells to osteopontin.
  • the adhering cells were detected at A570 nm. The results indicate that the lower a value at A570 nm, the less the binding between the integrin ⁇ 8-expressing K562 cells and osteopontin.
  • Adhesion of the positive control (PC) was set to 100.
  • the No.3 antibody was added at 0.05 ⁇ g/ml
  • the No.5 antibody and the No.26 antibody were added at 0.1 ⁇ g/ml
  • the results showed that the respective antibodies were found to exhibit an inhibitory activity of 50%.
  • the anti-integrin ⁇ 8 ⁇ 1 chicken monoclonal antibodies had a remarkable activity of inhibiting the binding between osteopontin and integrin ⁇ 8 ⁇ 1. This suggests that the above antibodies can be an extremely effective material as a therapeutic agent for various diseases involving the interaction between osteopontin and integrin ⁇ 8 ⁇ 1.
  • the above antibodies exert a similar effect on a ligand (e.g., fibronectin, tenascin, or vitronectin) other than osteopontin and can inhibit the binding to integrin ⁇ 8 ⁇ 1.
  • Example 7 Experiments Comparing Chicken-derived Anti-integrin ⁇ 8 ⁇ 1 Antibodies and Mouse-derived Anti-integrin ⁇ 8 ⁇ 1 Antibodies>
  • No.3 anti-integrin ⁇ 8 ⁇ 1 chicken monoclonal antibody hereinafter, sometimes referred to as "No. 3 chicken IgY”
  • an anti-integrin ⁇ 8 ⁇ 1 chicken-mouse chimeric antibody hereinafter, sometimes referred to as "No. 3 chicken-mouse chimeric IgG" which is a recombinant antibody derived from the above antibody
  • two kinds of an anti-integrin ⁇ 8 ⁇ 1 mouse monoclonal antibody (7A5 and 10A8). Then, their reactivity was compared.
  • 7A5 and 10A8 are antibodies described in a publication ( Sato et al., J Biol Chem., 2009, May 22, 284(21), 14524-36 , Epub Apr. 2, 2009), and have been provided from the authors in this research article.
  • Those 7A5 and 10A8 are antibodies which have been produced by immunizing a mouse with a recombinant soluble integrin ⁇ 8 ⁇ 1 as an antigen.
  • test antibodies as a primary antibody, was reacted at a concentration of 1 ⁇ g/ml with integrin ⁇ 8 ⁇ 1-expressing SW480 cells (at 4°C, for 30 min). After washing of the cells, an FITC-labeled secondary antibody was added and the mixture was reacted at 4°C for 30 minutes. After additional washing, FACS analysis was carried out. As a control, integrin ⁇ 8 ⁇ 1 expression-free cells were used.
  • FIG. 6 shows the results.
  • the No.3 chicken IgY and the No.3 chicken-mouse chimeric IgG had a large right shift, and were strongly positive for integrin ⁇ 8 ⁇ 1 (No.3 chicken IgY: 94.71% positive; No.3 chicken-mouse chimeric IgG: 98.53% positive).
  • two kinds of the integrin ⁇ 8 ⁇ 1 mouse monoclonal antibody were weakly positive (7A5: 2.59% positive; 10A8: 4.45% positive).
  • the above four kinds of the antibodies (No.3 chicken IgY, No.3 chicken-mouse chimeric IgG, 7A5, 10A8) were examined according to the following procedure. First, each of the above four kinds of the antibodies were reacted at a concentration of 5 ⁇ g/ml with the integrin ⁇ 8 ⁇ 1-expressing SW480 cells for 30 minutes. The cell-containing solution after the reaction was added to a plate on which mouse osteopontin (50 ⁇ g/ml) had been immobilized. Next, the solution was cultured for 45 minutes. Then, the cells were washed, fixed, and stained.
  • FIG. 7 shows the results. An activity of inhibiting cell adhesion was observed for the No. 3 chicken IgY, but not for 7A5 and 10A8.
  • the degree of cell adhesion of the No.3 chicken IgY-addition group was lower than that of the SW480 no-antibody-addition group.
  • the rate of inhibiting the cell adhesion by the No. 3 chicken IgY was considered to be 100%.
  • there was almost no difference regarding the 7A5-addition group and the 10A8-addition group in the degree of cell adhesion compared with a group in which integrin ⁇ 8 ⁇ 1-expressing SW480 cells had not been treated with antibody.
  • 7A5 and 10A8 can be considered to exert no activity of inhibiting the cell adhesion.
  • the anti-integrin ⁇ 8 ⁇ 1 antibodies as obtained in the Examples of the present application are remarkably superior in the aspects of both the activity of binding to integrin ⁇ 8 ⁇ 1 and the activity of inhibiting the binding between integrin ⁇ 8 ⁇ 1 and osteopontin, compared with the known conventional anti-integrin ⁇ 8 ⁇ 1 antibodies.
  • a production process having characteristic features has been adopted, including immunization using a chicken, use of the integrin ⁇ 8-expressing cell line as an antigen, cell panning using the integrin ⁇ 8-expressing cell line, and the like.
  • anti-integrin ⁇ 8 ⁇ 1 antibodies were obtained which 1) bound to integrin ⁇ 8 ⁇ 1 derived from both a human and a mouse, 2) had a high activity of binding to integrin ⁇ 8 ⁇ 1, and 3) inhibited binding of osteopontin to integrin ⁇ 8 ⁇ 1.
  • the resulting antibodies can be an industrially excellent material for a therapeutic agent, a diagnostic agent, a reagent, or the like.
  • the integrin ⁇ 8 ⁇ 1 is not limited to a human-derived one, but may include a mouse-derived one. Accordingly, it can be suitably used for research using a model mouse and treatment thereof. Many mouse strains have a known genetic background, have a property of a short generation time, and further are particularly important organisms used for development of a therapeutic or diagnostic agent because mice are susceptible to diseases similar to those of a human.
  • integrin ⁇ 8 ⁇ 1 activates PI3K ( Hynes RO., Cell, 2002, Sep. 20, 110(6), 673-87 ; and Farias et al., Biochem Biophys Res Commun., 2005, Apr. 1, 329(1), 305-11 ).
  • the PI3K is a kinase which phosphorylates the 3rd position of an inositol ring of inositol phospholipid, a component of a membrane.
  • the PI3K is known to be involved in various diseases.
  • integrin ⁇ 8 ⁇ 1 activates FAK ( Richard et al., Cell, Vol.110, 673-687, September 20, 2002 ; Shouchun Liu, Journal of Cell Science, 113, 3563-3571 (2000 ); and Littlewood et al., Nat Genet., 2000, Apr., 24(4), 424-8 ).
  • the FAK is an intracellular tyrosine kinase whose activated form interacts with many signaling molecules such as a Src-family kinase and a phosphatidylinositol 3-kinase.
  • the FAK is known to be involved in various diseases.
  • the antibodies as obtained in Examples 1 to 7 may inhibit the PI3K-FAK signal transduction, which is mediated through integrin ⁇ 8 ⁇ 1 from osteopontin.
  • the antibodies seem to exert a remarkable therapeutic effect on the above diseases (i.e., cancer, arthritis, glaucoma, or neuropathic pain).
  • the antibodies when used as a diagnostic agent, it seems to be possible to diagnose the above diseases by examining and comparing the modes of binding of the antibodies to integrin ⁇ 8 ⁇ 1 in, for example, cells, blood, serum, body fluid, or pathologic sections in any of the above diseases.
  • the excessive activation of PI3K or FAK is responsible for the diseases, and the activation may be caused by high expression of integrin ⁇ 8 ⁇ 1.
  • the binding level of the anti-integrin ⁇ 8 ⁇ 1 antibodies as obtained in Examples 1 to 7 increases.
  • the excessive activation of PI3K or FAK may be caused by high expression of osteopontin. In that case, due to competition with its ligand, the above binding level of the anti-integrin ⁇ 8 ⁇ 1 antibodies seems to decrease.
  • kidney morphogenesis failure Muller et al., Cell. 1997 Mar 7;88(5):603-13 .
  • inner hair cell deficiency Littlewood et al., Nat Genet., 2000, Apr., 24(4), 424-8
  • its high expression is observed in pulmonary fibrosis or hepatic fibrosis ( Levine et al., Am J Pathol., 2000, June, 156(6), 1927-35 ). Consequently, the antibodies as obtained in Examples 1 to 7 can be used as a probe to investigate an expression level of an integrin a8 chain in cells or tissues etc.
  • the antibodies seem to be able to be suitably used as a diagnostic agent for renal failure caused by kidney morphogenesis failure, inner ear disease caused by inner hair cell deficiency, pulmonary fibrosis, or hepatic fibrosis.
  • the binding level of the anti-integrin ⁇ 8 ⁇ 1 antibodies increases.
  • the competition with osteopontin seems to decrease the binding level of the anti-integrin ⁇ 8 ⁇ 1 antibodies.
  • the antibodies seem to be able to be suitably used as a prenatal diagnostic agent for kidney morphogenesis failure or inner hair cell-deficiency.
  • the antibodies as obtained in Examples 1 to 7 seem to be an extremely effective material for a reagent used in integrin ⁇ 8 ⁇ 1-related basic research or regenerative medicine etc.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (7)

  1. Antikörper gegen Integrin α8β1, der die Bindung zwischen Integrin α8β1 und seinem Liganden hemmt, wobei der Antikörper an Integrin α8β1, abgeleitet von Säugetieren verschiedener Spezies, bindet, dadurch gekennzeichnet, dass der Antikörper umfasst:
    CDR1 der schweren Kette mit einer in SEQ ID Nr. 1 dargestellten Aminosäuresequenz;
    CDR2 der schweren Kette mit einer in SEQ ID Nr. 2 dargestellten Aminosäuresequenz;
    CDR3 der schweren Kette mit einer in SEQ ID Nr. 3 dargestellten Aminosäuresequenz;
    CDR1 der leichten Kette mit einer in SEQ ID Nr. 10 dargestellten Aminosäuresequenz;
    CDR2 der leichten Kette mit einer in SEQ ID Nr. 11 dargestellten Aminosäuresequenz;
    und
    CDR3 der leichten Kette mit einer in SEQ ID Nr. 12 dargestellten Aminosäuresequenz.
  2. Antikörper gegen Integrin α8β1 nach Anspruch 1, wobei der Antikörper durch Verwendung von Integrin α8β1 exprimierenden Zellen als Antigen erhalten wird.
  3. Antikörper gegen Integrin α8β1 nach einem der Ansprüche 1 bis 2, wobei der Antikörper an Integrin α8β1, abgeleitet von einem von einem Menschen und einer Maus, bindet.
  4. Antikörper gegen Integrin α8β1 nach Anspruch 1 bis 3, wobei der Ligand ein oder mehrere Liganden, ausgewählt aus der Gruppe bestehend aus Osteopontin, Fibronectin, Tenascin und Vitronectin, ist.
  5. Antikörper gegen Integrin α8β1 nach einem der Ansprüche 1 bis 4, wobei der Antikörper ein Antikörperfragment ist, das die Bindung zwischen Integrin α8β1 und seinem Liganden hemmt, wobei das Antikörperfragment an Integrin α8β1, abgeleitet von Säugetieren verschiedener Spezies, bindet.
  6. Polynucleotid, umfassend eine Nucleotidsequenz, die den Antikörper nach einem der Ansprüche 1 bis 5 codiert.
  7. Verfahren zum Hemmen einer Bindung zwischen Integrin und seinem Liganden in vitro, umfassend Inkontaktbringen von einem Integrin a8ßl mit dem Antikörper gegen Integrin a8ßl nach einem der Ansprüche 1 bis 5.
EP10824931.9A 2009-10-21 2010-10-19 Integrin-alpha8beta1-spezifischer monoklonaler antikörper Active EP2495319B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP18209961.4A EP3483267A3 (de) 2009-10-21 2010-10-19 Integrin-alpha 8-beta-1-spezifischer monoklonaler antikörper

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009242891 2009-10-21
JP2010085473 2010-04-01
PCT/JP2010/068374 WO2011049082A1 (ja) 2009-10-21 2010-10-19 インテグリンα8β1特異的モノクローナル抗体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP18209961.4A Division EP3483267A3 (de) 2009-10-21 2010-10-19 Integrin-alpha 8-beta-1-spezifischer monoklonaler antikörper

Publications (3)

Publication Number Publication Date
EP2495319A1 EP2495319A1 (de) 2012-09-05
EP2495319A4 EP2495319A4 (de) 2013-07-03
EP2495319B1 true EP2495319B1 (de) 2018-12-05

Family

ID=43900306

Family Applications (2)

Application Number Title Priority Date Filing Date
EP10824931.9A Active EP2495319B1 (de) 2009-10-21 2010-10-19 Integrin-alpha8beta1-spezifischer monoklonaler antikörper
EP18209961.4A Withdrawn EP3483267A3 (de) 2009-10-21 2010-10-19 Integrin-alpha 8-beta-1-spezifischer monoklonaler antikörper

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP18209961.4A Withdrawn EP3483267A3 (de) 2009-10-21 2010-10-19 Integrin-alpha 8-beta-1-spezifischer monoklonaler antikörper

Country Status (6)

Country Link
US (1) US8658770B2 (de)
EP (2) EP2495319B1 (de)
JP (1) JP5765814B6 (de)
CA (1) CA2778401C (de)
TW (1) TWI508743B (de)
WO (1) WO2011049082A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2821415T3 (da) * 2012-02-29 2021-04-26 Otsuka Pharma Co Ltd Antistof mod anti-lipoarabinomannan og immunoassay til syrefast bacillær infektion under anvendelse af antistoffet
CA2875200C (en) 2012-03-28 2024-02-20 Hiroshima University Fibrosis suppression by inhibiting integrin alpha8beta1 function
JP6531987B2 (ja) * 2015-10-01 2019-06-19 国立大学法人名古屋大学 腎疾患診断のためのエクソソーム回収法
EP3430056A4 (de) * 2016-03-15 2019-11-20 The Regents of the University of California Verfahren und zusammensetzungen für die behandlung und vorbeugung von mit alpha-8-beta-1-integrin-assoziierten krankheiten
CA3022961A1 (en) 2016-05-02 2017-11-09 Tetragenetics, Inc. Anti-kv1.3 antibodies, and methods of production and use thereof
WO2019107671A1 (ko) * 2017-11-29 2019-06-06 서울대학교 산학협력단 항-ros1 항체 및 그의 용도
CN110872354B (zh) * 2018-09-04 2022-11-01 华瑞同康生物技术（深圳）有限公司 哺乳动物细胞重组抗人tk1的鸡源的单克隆抗体、单链抗体及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS63161602A (ja) 1986-12-25 1988-07-05 Kawasaki Steel Corp 高周波磁気特性に優れた圧粉磁心
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
US6303766B1 (en) * 1999-05-14 2001-10-16 Virginia Tech Intellectual Properties, Inc. Soybean phytase and nucleic acid encoding the same
JP2003104909A (ja) 2001-07-26 2003-04-09 Santen Pharmaceut Co Ltd Ｐｉ３キナーゼ阻害作用を有する化合物を有効成分とする緑内障治療剤
GB0302699D0 (en) * 2003-02-06 2003-03-12 Univ Bradford Immunoglobulin
AU2005277641A1 (en) 2004-08-16 2006-03-02 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
JP4452884B2 (ja) 2005-03-01 2010-04-21 国立大学法人広島大学 抗体およびその利用
JP2007063205A (ja) 2005-08-31 2007-03-15 Japan Science & Technology Agency 神経因性疼痛治療剤
RU2429016C2 (ru) 2006-05-31 2011-09-20 Астеллас Фарма Инк. Гуманизированное антитело против остеопонтина человека

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RUDIKOFF S ET AL: "Single amino acid substitution altering antigen-binding specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 79, no. 6, 1 March 1982 (1982-03-01), pages 1979 - 1983, XP002683593, ISSN: 0027-8424 *
STEPHAN DUEBEL ED - STEFAN DÜBEL: "Handbook of Therapeutic Antibodies Chapter 6", 1 January 2007, HANDBOOK OF THERAPEUTIC ANTIBODIES, WILEY-VCH, WEINHEIM, PAGE(S) 119 - 144, ISBN: 978-3-527-31453-9, XP007913671 *

Also Published As

Publication number Publication date
TWI508743B (zh) 2015-11-21
US8658770B2 (en) 2014-02-25
TW201119678A (en) 2011-06-16
WO2011049082A1 (ja) 2011-04-28
JPWO2011049082A1 (ja) 2013-03-14
CA2778401C (en) 2019-08-13
EP3483267A3 (de) 2019-07-31
US20120237530A1 (en) 2012-09-20
EP3483267A2 (de) 2019-05-15
EP2495319A1 (de) 2012-09-05
JP5765814B6 (ja) 2018-06-27
CA2778401A1 (en) 2011-04-28
EP2495319A4 (de) 2013-07-03
JP5765814B2 (ja) 2015-08-19

Similar Documents

Publication Publication Date Title
EP2495319B1 (de) Integrin-alpha8beta1-spezifischer monoklonaler antikörper
WO2019184912A1 (zh) 抗cd47抗体及其用途
US8563696B2 (en) Antibody specifically binding to c-Met
KR101451546B1 (ko) Ｇｍ-ｃｓｆ 수용체에 대한 결합 성분
JP5982698B2 (ja) Ｄｌｌ４に特異的に結合する新規モノクローナル抗体及びその用途
US11779629B2 (en) Compositions comprising cyclic peptides derived from an A-beta peptide
CN116410316A (zh) 抗cd47抗体及其用途
US11905318B2 (en) Cyclic compound/peptide comprising an A-beta13-16 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-beta13-16 peptide
US20210154315A1 (en) N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
US11970522B2 (en) Cyclic compound/peptide comprising an A-beta15-18 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-BETA15-18 peptide
JP5273689B2 (ja) ヒトプロスタグランジンｅ２受容体ｅｐ４に対する抗体
JPWO2011049082A6 (ja) インテグリンα８β１特異的モノクローナル抗体
US20180326027A1 (en) Epitopes in amyloid beta and conformationally-selective antibodies thereto
KR20180094877A (ko) 아밀로이드 베타 내 c-말단 에피토프 및 이에 대해 구조적으로 선택적인 항체
JP2022548764A (ja) Ｌｉｌｒｂ２に対するシングルドメイン抗体
WO1999060025A1 (fr) Anticorps recombines de gene
JP3679406B2 (ja) 遺伝子組換え抗体

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120515

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130604

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101ALI20130528BHEP

Ipc: A61P 25/04 20060101ALI20130528BHEP

Ipc: G01N 33/566 20060101ALI20130528BHEP

Ipc: A61P 35/00 20060101ALI20130528BHEP

Ipc: C12N 15/09 20060101AFI20130528BHEP

Ipc: A61K 39/395 20060101ALI20130528BHEP

Ipc: C12P 21/08 20060101ALI20130528BHEP

Ipc: C07K 16/46 20060101ALI20130528BHEP

Ipc: A61P 27/06 20060101ALI20130528BHEP

Ipc: A61P 19/02 20060101ALI20130528BHEP

17Q First examination report despatched

Effective date: 20160603

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20180612

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1073078

Country of ref document: AT

Kind code of ref document: T

Effective date: 20181215

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602010055678

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: HEPP WENGER RYFFEL AG, CH

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20181205

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1073078

Country of ref document: AT

Kind code of ref document: T

Effective date: 20181205

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190305

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190306

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190405

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190405

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602010055678

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

26N No opposition filed

Effective date: 20190906

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191019

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20191031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191019

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20101019

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20221123

Year of fee payment: 13

Ref country code: FR

Payment date: 20221116

Year of fee payment: 13

Ref country code: DE

Payment date: 20221031

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20221124

Year of fee payment: 13